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Background:Many HIV databases and applications focus on a limited
domain of HIV knowledge. Since even a ‘‘simple’’ organism like HIV
represents a very complex system with many interacting elements,
the fractured structure of existing databases and applications likely
limits our ability to investigate and understand HIV. To facilitate
research, therefore, we have built HIVToolbox, which integrates
much of the knowledge about HIV proteins and presents the data in
an interactive web application. HIVToolbox allows quick and
convenient hypotheses generation, experiment interpretation, and
potential new drug structure creation.
Methods: HIVToolbox was built as a standard three-tier J2EE web
application, consisting of 1) an underlying relational MySQL database,
2) a set of standard Java data access objects that pull data from the
database, and 3) a set of dynamic web pages the user interacts with.
HIV-1 data from external sources such as the Protein Data Bank, NCBI,
Los Alamos, etc. was collected, curated, and stored in the HIVToolbox
database. Additional data, such as homology and position statistics
matrices, was generated from existing data. Since version 1, drug
binding site and drug resistant mutation data has also been added.
Results: HIVToolbox was used to create several new hypotheses
about HIV-1 integrase, including predicting the location of a CK2
phosphorylation site, which was later confirmed by experiment.
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Figure 1. Protease with drug Amprenavir shown [Interactive HIV protein page].
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A new version of HIVToolbox support display of the 3D locations
of drug resistant mutations on surface plots of HIV proteins and
the drug binding sites for structures of complexes of HIV proteins
with drugs.
Conclusion: HIVToolbox is an open-access web application that
allows virologists and structural biologists to access detailed
information about HIV-1 proteins, such as sequence, structure,
functional sites and relationships, homology, drug binding sites,
and drug resistant mutations, and to immediately see the relation-
ships between any or all of them. Weblink: [http://hivtoolbox.bio-
toolkit.com]
A7 - Virus-specific humoral immunity
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Production and characterization of human anti-V3
monoclonal antibodies from Indian clade C human
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Background: Analysis of human monoclonal antibodies (mAbs)
developed from HIV-1 infected donors have enormously contributed
to the identification of neutralization sensitive epitopes on the HIV-1
envelope glycoprotein. The third variable region (V3) is a crucial
target on gp120, primarily due to its involvement in co-receptor
(CXCR4 or CCR5) binding and presence of epitopes recognized by
broadly neutralizing antibodies.
Methods: Thirty-three HIV-1 seropositive drug naive patients (18
males and 15 females) within the age range of 20-57 years
(median33 years) were recruited in this study for mAb production.
The mAbs were selected from EBV transformed cultures with
conformationally constrained Cholera-toxin-B containing V3C (V3C-
CTB) fusion protein. We tested the mAbs for their binding with HIV-1
derived proteins and peptides by ELISA and for neutralization against
HIV-1 viruses by TZM-bl assays.
Results: We isolated three anti-V3 mAbs, 277, 903 and 904 from the
cells of different individuals. The ELISA binding revealed a subtype-C
and subtype-A specific binding of antibody 277 and 903 while 904
exhibited cross reactivity also with subtype-B V3. Epitope mapping of
mAbs with overlapping V3 peptides showed exclusive binding to V3
crown. The antibodies displayed high and low neutralizing activity
against 2/5 tier 1 and 1/6 tier 2 viruses respectively. Overall, we
observed a resistance of the tier 2 viruses to neutralization by the anti-
V3 mAbs, despite exposure of the epitopes recognized by these
antibodies on the native viruses, as determined by intact virion binding
assay with two representative subtype-C and B viruses (Du156.12 and
JRFL).
Conclusion: Our study suggests that the anti-V3 antibodies derived
from subtype-C infected Indian patients display neutralization
potential against tier 1 viruses. Defining the epitope specificities of
these mAbs and further experimental manipulations will be helpful
in identification of epitopes, unique to clade C or shared with non-
clade C viruses, for immunogen design.
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Background: One major obstacle to induce bNAbs resides in the high
variability of the viral envelope and structural mechanisms hiding
crucial epitopes. Besides, maturation of bNAbs against HIV represents
a difficult process that can be impaired by the immunodeficiency
associated with HIV infection. We have explored the hypothesis that
preserved B cell function in LTNPs could result in the production of
bNAbs at higher frequency and increased affinity in comparison with
HIV progressors.
Methods: Samples (142) from the cohort of LTNPs (median RNA
copies/ml: 87, median CD4: 802 cells/ml) were kindly provided by
the HIV BioBank integrated in the Spanish AIDS Research Network
(RIS). A control population of 191 untreated patients (median RNA
copies/ml: 10,241, median CD4: 567 cells/ml) from Hospital Clinic,
Barcelona, was analyzed. Sera at 1/200 and 1/2000 dilutions were
preincubated with Env recombinant viruses harboring a luciferase
gene and then added to U87.CD4.CXCR4/CCR5. bNAbs specificities
were studied by ELISA using mutated gp120 that abrogates antibody
binding, competition ELISA with biotinylated antibodies, neutraliza-
tion assays with mutated viruses and peptide competition neutra-
lization assays.
Results: The percentage of elite neutralizers was higher in the LTNPs
(9.3%) than in the control population (3.7%). Broadly neutralizing sera
were screened for the presence of epitope-specific antibodies. CD4
binding site antibodies were detected in several sera. To determine
whether these antibodies were responsible for broad neutralization,
competition neutralization assays using RSC3 (antigenically resur-
faced glycoprotein containing the CD4bs) were performed. RSC3
addition inhibited neutralization mediated by 16.7% of sera in LTNPs
and 12.5% sera of the control population. Anti-MPER antibodies were
detected in 50% individuals of both populations, including several
sera with 4E10-like antibodies. Glycan-dependent HIV-1 NAbs were
more abundant in LTNPs (66%) than in control population (37%).
Conclusion: Broad humoral immune responses against HIV-1 were
more common among LTNP than a control population of untreated
HIV-1-infected donors.
A8 - Virus-specific cellular immunity
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Background: HIV/SIV primarily infect activated CD4 T cells, but
can infect macrophages. Because of the relatively small percentage of
infectedmacrophages, the interaction between antigen-specific CD8
T cells and infected macrophages in HIV/SIV infection has been poorly
studied. We, therefore, sought to determine whether SIV-specific
CD8 T cells could control viral replication in infected macrophages.
Methods: We wanted to ascertain whether ex vivo tetramer-
sorted SIV-specific CD8 T cells could suppress viral replication in
SIVmac239/316e- and SIVsmE660-infected macrophages using a
recently developed 48-hour viral suppression assay. We reasoned
that freshly sorted CD8 T cells might be more representative of
the in vivo properties of CD8 T cells than in vitro cultured cell lines
and clones.
Results: Surprisingly, both ex vivo tetramer-sorted SIV-specific CD8
T cells and bulk CD8 T cells that eliminated and suppressed viral
replication in SIV-infected CD4 T cells were inefficient at controlling
viral replication in SIV-infected macrophages. Our data suggest that
macrophages may be an important reservoir for SIV because it may
be difficult for SIV-specific CD8 T cells to suppress viral replication
in this particular cell type.
Conclusion: It is possible, therefore, that while AIDS virus-infected
macrophages only constitute a small percentage of all virus-infected
cells, they may be relatively resistant to CD8 T cell-mediated lysis
and continue to produce virus over long periods of time. Thus,
macrophages could actually be contributing significantly to viral
production. Induction of HIV/SIV-specific CD8 T cells capable of
killing infected macrophages or preventing establishment of the
macrophage reservoir HIV might be critical for controlling viral
replication.
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Comparative activity of IgA mediated antibody dependent
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Figure 1.
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Background: The potential role of ADCC in prevention of infection is
suggested by the RV144 HIV vaccine trial where non-neutralizing
antibodies contributed to protection against infection with HIV.
Studies from Kenya showed that HIV specific IgA in cervical fluid
was present in uninfected sex workers. We aimed to analyze
cervicovaginal lavage fluid(CVL) from 2 seroconverters (SC) and 10
highly exposed seronegative women who had unprotected sex with
known positive partners.
Methods: A 51Cr-release assay with natural killer cells or monocytes
as effectors was used to measure IgG or IgA mediated ADCC against
clade specific gp120 coupled target cells. We analyzed CVL from ESN
at one visit, and SC at intervals from one yr pre-seroconversion (PSC)
to 6.5 yr after seroconversion (ASC). We evaluated activity at 4, 10
fold serial dilutions starting with a 1/10 dilution.
Results: Figure 1 (top)shows shows minimal to no activity of IgG
mediated ADCC in the CVL of 10 ESN. Figure 1(bottom) shows IgA
mediated ADCC in the CVL of the same 10 ESN. 4 patients show
significant activity above background activity. At the peak dilution,
patient 4 shows 27.3% Specific Release (SR), patient 6 shows 14.5
%SR, patient 8 shows 17.9 %SR and patient 10 shows 17.6 %SR.
Figure 2 and 3 shows no IgA mediated ADCC activity in CVL of 2
seroconverters from PSC to 6.5 years ASC even while IgG activity is
present in later visits.
Conclusion: HIV IgA in CVL samples was associated with ADCC and
lack of HIV infection in exposed women, indicating that genital HIV IgA
may contribute to protection from infection. Further studies need to
be done to determine if IgA mediated ADCC antibodies may be
protective in ESN.
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The colocalization potential of HIV-specific CD8 and
CD4 T cells is mediated by integrin b7 but not CCR6 and
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Background: CD4 T-cells from gut-associated lymphoid tissues
(GALT) are major HIV-1 targets. Recruitment of excess effector CD8
T-cells in the proximity of target cells is critical for the control of viral
replication. We investigated the colocalization potential of HIV-
specific CD8 and CD4 T-cells into the GALT and explored the role
of retinoic acid (RA) in regulating this process in a cohort of HIV-
infected subjects with slow disease progression (SP).
Methods: Five SP subjects were available for this study: median CD4
counts 670 cells/ml, plasma viral load 3.27 log10 HIV-RNA copies/ml,
and 15 years of infection. PBMC were exposed to HIV peptides or
CMVpp-65 protein in the presence or absence of all-trans RA (ATRA)
or the RA antagonist LE540. The expression of trafficking molecules
on antigen specific T-cells was analyzed by flow cytometry using the
CFSE assay.
Results: The expression of the gut-homing molecules integrin b7,
CCR6, and CXCR3 was identified as a ‘‘signature’’ for HIV-specific but
not CMV-specific CD4 T-cells, thus providing a new explanation for
their enhanced permissiveness to infection in vivo. HIV-specific CD8
T-cells expressed high levels of integrin b7 and CXCR3; however CCR6
was detected at superior levels on HIV-specific CD4 versus CD8 T-
cells. ATRA upregulated the expression of integrin b7 but not CCR6
on HIV-specific T-cells.
Conclusion: HIV-specific CD8 T-cells may colocalize in excess with
CD4 T-cells into the GALT via integrin b7 and CXCR3, but not CCR6.
Figure 2.
Figure 3.
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Considering our previous findings that CCR6CD4 T-cells are
major HIV targets, a limited ability of CD8 T-cells to migrate in
the vicinity of CCR6CD4 T-cells may facilitate HIV dissemination at
mucosal sites. In addition to other previously described T-cell
features (e.g., antiviral properties, poly-functionality, and exhaus-
tion), the colocalization potential of CD4 and CD8 T-cells
represents a new parameter to consider for predicting the efficacy
of anti-HIV responses.
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Enhanced TCR affinity imparts specificity to reverse
transcriptase inhibitor resistance-associated mutations
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Background: An attractive approach for restoring CTL activity to HIV-
1 infected individuals is the adoptive transfer of autologous CD8 T
cells that have been transduced with an HIV-1 specific TCR.
Previously, we described an HLA-A2-SL9 specific TCR that when
introduced into CD8 T cells could control HIV-1 replication in an in
vitro suppression assay. Given that the success of HAART is based, in
part, on attacking multiple targets, we isolated an additional HLA-A2
restricted, HIV-1 specific TCR targeting the HIV-1POL sequence
YQYMDDLYV. This epitope is of great clinical relevance because it
lies within the active site of Pol and is a target of many reverse
transcriptase inhibitors.
Methods: By surface plasmon resonance, we defined the Kd of this
wild type TCR to be 6.7mM and t1/2 to be 2.7s. Using phage display, a
panel of affinity enhanced A2-YV9 TCRs were obtained with Kd values
ranging from 5.1 to 0.3mM.
Results: When introduced into CD8 T cells by lentiviral vectors,
the A2 YV9 specific TCRs were highly specific for the wild type
epitope. In contrast to what we previously determined for CD8 T cells
transduced with the wild type A2-SL9 specific TCR, we observed that
the A2-YV9 specific T cells could respond in a polyfunctional manner
by simultaneously producing TNF-a, IFN-g, IL-2, and MIP1-b when
presented with a wide range of peptide concentrations. Moreover,
affinity enhanced A2-YV9 specific CD8 T cells were able to recognize
and respond to several variants of the wild type sequence, including
those responsible for resistance to NNRTI and NRTI such as
Nevirapine, Didanosine and Efavirenz.
Conclusion: Together, our data suggest that adoptive transfer of
these A2-YV9 specific CD8 T cells presents great potential for
augmenting available treatments and imparting additional control
to HIV-1 infected individuals experiencing drug resistance.
A9 - Immune responses in resistant
cohorts: elite controlers and exposed
uninfected
MOAA0201
HIV controllers maintain a population of highly efficient Th1
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Background: HIV Controllers are rare individuals who spontaneously
control HIV replication in the absence of antiretroviral therapy.
To identify parameters of the CD4 response that may contribute to
viral control, rather than merely reflect a persistently low viremia,
we compared the T helper profile in two groups of patients with
more than 10 years of viral suppression: HIV Controllers from the
ANRS CO18 cohort (n26) and efficiently treated patients (n16).
Methods: Cells specific for immunodominant Gag and CMV peptides
were evaluated for the production of 10 cytokines and cytotoxicity
markers, and were also directly quantified ex vivo by MHC class II
tetramer staining.
Results: HIV Controller CD4 T cells were characterized by a higher
frequency of IFN-g production, perforin/CD107a expression, and
polyfunctionality in response to Gag peptides. While IL-4, IL-17, and
IL-21 production did not differ between groups, treated patients cells
produced more IL-10 in response to Gag and CMV peptides, pointing
to persistent negative immunoregulation after long-term antiretro-
viral therapy. Gag293 tetramer-positive cells were detected at high
frequency (0.15%) and correlated positively with IFN-g producing
CD4 T cells in the Controller group (R0.84; P0.01). Tetramer-
positive cells were fewer in the HAART group (0.04%) and did not
correlate with IFN-g production, supporting the notion of a
persistent immune dysfunction in HIV-specific CD4 T cells of
treated patients.
Conclusion: HIV Controllers maintained a population of highly
efficient Th1 effectors directed against Gag in spite of a persistently
low antigenemia, while patients treated in the long-term showed a
loss of CD4 effector functions.
We previously reported that HIV Controllers harbored a unique po-
pulation of CD4 T cells expressing high avidity TCRs directed against
Gag293. We propose that high avidity drives continuous Th1 effector
differentiation in response to low antigen concentrations and explains
the persistence of an activated antiviral response in HIV Controllers.
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Natural control of HIV infection is associated with an
isotype switched IgG antibody response to HIV core
antigens in patients with ‘non-protective’ HLA-B alleles
M. French1, R. Center2, K. Wilson3, I. Fleyfel1, S. Fernandez1 and
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Background:Natural control of HIV infection is associatedwith CD8 T
cell responses to HIV core antigens, encoded by Gag, restricted by
‘protective’ HLA-B alleles (HLA-B27, -57, -58). Slower progression of
HIV infection is associatedwith antibodies to HIVcore proteins butme-
chanisms are unclear. Antibody responses that have isotype switched
to IgG2may be particularly effective.We have investigated this further.
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Methods: Plasma from 32 HIV controllers (HIV RNAB2000 copies/
mL, including 14 elite controllers) and 21 ART-naive non-controllers
(CD4 T cell countB100/uL) were assayed for IgG1 and IgG2
antibodies to non-recombinant HIV proteins by western blot (WB)
assay and to recombinant (r) p55 (Gag) and gp140 (Env) by ELISA.
A positive antibody response was defined as a WB band score of 4 or
an ELISA optical density 2SD of non-HIV sera for rp55 antibodies.
Antibodies to rgp140 were titred. Controllers were HLA typed by
sequenced-based typing using genomic DNA.
Results: Controllers had a positive IgG1 or IgG2 antibody response to
one or more core protein (p17, p24) on WB more often than non-
controllers (75% vs 28.6%, p0.0016 and 22% vs 0, p0.034,
respectively). Also, 12.5% of controllers but no non-controllers had a
positive IgG2 antibody to rp55 (p0.14). When results of WB assays
and ELISA were combined, 34% of controllers but no non-controllers
had positive IgG2 antibodies to core antigens (p0.04). Positive
IgG2 antibodies to core antigens were more common in patients
without ‘protective’ HLA-B alleles (57%) than patients with these
alleles (16.5%) (p0.026). Positive IgG1 antibodies to Pol-encoded
proteins were also more common in controllers (p0.0003) but
IgG2 antibodies were not detected. IgG1 and IgG2 antibodies to
envelope antigens showed few differences.
Conclusion: An isotype switched IgG antibody response to HIV core
antigens is associated with control of HIV infection in patients
without ‘protective’ HLA-B alleles.
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ZNDR1 gene affects host susceptibility to HIV-1 infection
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Background: A recent genome-wide association study (GWAS) of
host determinants for HIV-1 disease revealed that single nucleotide
polymorphisms (SNPs) near genes HLA-C and ZNRD1 were associated
with setpoint HIV-1 viral load and disease progression. ZNRD1 has
also been identified as a host protein required by HIV-1 life cycle in a
genome-wide functional genomic study.
Methods: We investigated the effects of 13 SNPs in the ZNRD1
region on HIV-1 infection and progression in five U.S-based
treatment-naive HIV-1 longitudinal cohorts consisting of homosex-
uals, hemophiliacs and injection drug users (IDUs) (n1028). Allelic
frequencies were compared between HIV-1 seronegatives (SN) and
seroconverters (SC) with further analysis focusing on high-risk
exposed HIV-1-uninfected individuals (HREU) compared to HIV-1
seroconverters (SC). Among HIV- 1 seroconverters, variation in time
to clinical AIDS was assessed by haplotype. Electrophoretic mobility
shift assay (EMSA) was used to assess the associated SNP’s potential
to alter DNA-protein interactions.
Results: A haplotype in the ZNRD1 gene showed significant
association with decreased risk of HIV-1 acquisition (OR0.65,
95% CI 0.47-0.89), independent of the effect of HLA-C rs9264942. The
tag SNP allele in the ZNRD1 promoter region causes a loss of nuclear
factor binding, as revealed by EMSA. This differential binding was
further shown to be cell-specific, occurring in Hela epithelial cells
instead of Jurkat T-cells (stimulated or unstimulated), suggesting its
regulatory role in mucosal epithelial barriers influence HIV-1
transmission. Indeed, this infection effect was not observed in HIV-
1 infected IDUs (OR0.82, 95% CI, 0.44-1.54). On the other hand,
SNPs and haplotypes for ZNRD1 modestly affect progression rate to
AIDS.
Conclusion: This study provided novel evidence supporting a
direct role of ZRND1 in modulating HIV and identified a ZNRD1
allele as a host resistant factor to HIV-1 acquisition. (Funded by NCI
HHSN26120080001E)
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Evidence for T cell immune quiescence in the genital
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Background: Understanding the early events during heterosexual HIV
transmission at the genital mucosa is necessary to develop a safe and
efficacious HIV microbicide or vaccine. A recent workshop high-
lighted the benefits of studying Highly Exposed Seronegative (HESN)
individuals in order to identify and describe correlates of HIV
protection. In an HESN cohort of commercial sex workers in Nairobi,
Kenya, we have described a state of reduced systemic T cell immune
activatio termed Immune Quiescence. However, the extent of
Immune Quiescence at the genital mucosal is not known. This study
characterized the female genital mucosal profile of cells, cytokines
and chemokines involved in immune activation and lymphocyte
recruitment among HESN.
Methods: CVL and plasma from commercial sex workers from the
Majengo clinic in Nairobi, Kenya (57 HIV- followed forB3 years; 68 HIV
infected and 55 HESN followed for 7 years) were analysed for the
presence of 22 cytokines/chemokines and five antiproteases pre-
viously associated with resistance to HIV infection. Activation of
cervico vaginal cells was analysed by multiparametric flow cytometry.
Results: HESN women have a unique pattern of mucosal chemokine/
cytokine expression. HESN subjects showed lower expression of MIG,
IP-10 and IL-1a as well as higher levels of antiproteases. Among the
HESN women there was a distinct chemokine gradient between the
blood and genital mucosa relative to control women.
Conclusion: MIG and IP-10 are important regulators of T cell
trafficking to the genital mucosa while IL-1a is an indicator of
immune activation. The reduced levels of these cytokines/chemo-
kines together with the unique correlations observed with anti-
protease expression among HESN women suggest that the Immune
Quiescent phenotype extends to the female genital tract. Reducing
the number of activated CD4 T cells in the FGT could limit cellular
targets for HIV infection and may be an important component to
resisting HIV infection.
WEPDA0105
Highly HIV exposed seronegative (HESN) sex workers from
Nairobi, Kenya have altered innate mucosal immune
responses at the level of the female genital tract
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Background: For 26 years a group of HESN women from Nairobi,
Kenya who can be epidemiologically described as relatively resistant
to HIV infection have provided clues towards the identification of
natural correlates of protection against HIV-1 infection. Studies of
these HIV-1-resistant women suggest they posses a unique mucosal
environment which includes the overexpression of specific antipro-
teases and a unique proinflamatory cytokine expression patern. Here
we describe how these factors contribute to protection against HIV
infection during mucosal transmission.
Methods: Cervical lavage fluid (CVL) from 277 women were collected
from 76 HIV-1-resistant, 120 HIV-1 uninfected, and 97 HIV-1 infected
women. CVL protein was analyzed both independently by SELDI-TOF
MS and as pooled groups by 2D-LC-FTICR MS. Of the more than 350
unique proteins identified 29 proteins were differentially expressed
( 2-fold cutoff) between HIV-1-resistant women and controls.
These findings were confirmed by traditional ELISA and quantitative
Western Blot (WB) analysis.
Results: The majority of overexpressed proteins were serpins, their
breakdown products (p2.2 x 108), and other antiproteases, as
well as innate factors with known anti-HIV-1 activity. The over-
expression of specific serpins and an epithelial-derived antiproteases
was confirmed by ELISA and WB (p0.004, p0.05, and p0.02).
Underexpressed proteins in HIV-resistant women included inflam-
matory proteases and immune response factors. Cytokine/chemo-
kine analysis revealed that antiprotease expression correlated with
pro-inflammatory cytokines (pB0.0001). However, this was inde-
pendent of the elevated antiprotease expression observed in HIV-
resistant women who in fact expressed reduced levels of certain
inflammatory chemokines (p0.018).
Conclusion: HIV-1-resistant women have elevated acute phase
response antiproteases that may regulate inflammation in the female
genital tract. Coupled with elevated expression of anti-viral proteins,
this may provide a mucosal environment less susceptible to HIV-1.
These antiproteases might contribute to a natural protective environ-
ment against HIV-1-infection. Understanding this mechanism could
aid in microbicide or therapeutic development.
THPDA0103
Low magnitude and frequency of HSV-2-specific interferon
gamma-producing CD4 and CD8 T cell responses
detected in HIV-1 heterosexual discordant couples
T.N. Dieye1, A. Chentouffi2, M. Camara1, S. Sarr1, M.V. Tran2,
M. Seydi3, G. Dasgupta2, M. Fall1, G. Daneau4, P.A. Diaw1, L. Kestens4,
P.S. Sow3, S. Mboup1 and L. Benmohamed2
1Cheikh Anta Diop University, Dakar, Senegal, Laboratory of
Immunology, Department of Bacteriology & Virology, Centre
Hospitalier Universitaire Le Dantec, Dakar, Senegal. 2University of
California Irvine, Laboratory of Cellular and Molecular Immunology,
The Gavin Herbert Eye Institute and Department of Ophthalmology,
Irvine, United States. 3Cheikh Anta Diop University, Dakar, Senegal,
Centre Hospitalier Universitaire de Fann, Dakar, Senegal. 4Institute of
Tropical Medicine, Antwerp, Belgium, Department of Microbiology,
Laboratory of Immunology, Antwerp, Belgium
Presenting author email: tndieye@yahoo.co.uk
Background: Herpes simplex virus type 2 (HSV-2), the most frequent
cause of genital ulcer disease (GUD), has been shown to play a more
important role than any other sexually transmitted infections (STIs)
in driving HIV prevalence in Africa. In turn, HIV-1 infection leads to
more frequent HSV-2 reactivations and shedding. The exact immune
mechanisms involved in this virological negative immuno-synergy
are unknown. In the present study we sought to assess whether HIV
co-infection would affects HSV-specific T cell immunity.
Methods: Nineteen HSV peptides, derived from HSV-2 glycoproteins
gB and gD, were used to analyze the frequency and the magnitude of
HSV-2-specific IFN-g-producing CD4 and CD8 T cell responses in
30 HSV-2 seropositive patients and 17 HSV-2 seronegative individuals
in a cohort of heterosexual Senegalese HIV-discordant couples, using
ELISpot assay. HIV RNA viral load has been run for HIV infected
subjects and CD4 count ran for all subjects using a flow cytometry
method.
Results: The magnitude and frequency HSV-2-specific T cell re-
sponses was compared between 21 HSV-2 co-infected with HIV-1 and
9 HSV-2 mono-infected individuals. A significantly higher magnitude
of IFN-g-producing T cell responses were observed in HSV-2 infected
patients compared to seronegative individuals (median, 61 vs. 0
spots/106 PBMC, P0.001). Moreover, twenty-four (80%) out of 30
HSV-2 seropositive patients showed significant HSV-2-specific IFN-g-
producing T cell responses compared with only 6 (35%) out of 17
HSV-2 negative subjects (PB0.001). The HSV-2 mono-infected
patients showed significantly higher magnitude of HSV-2-specific T
cell responses compared to HSV/HIV co-infected patients (median,
140 vs. 42 spots/106 PBMC, P0.024).
Conclusion: Our finding suggest that co-infection with HIV-1 in HSV-
2-infected patients might be associated with reduced HSV-2 cellular
immune responses. However, the interaction between HIV and HSV-2
appears complex, and precise longitudinal studies will be required to
dissect their exact temporal relationship.
A10 - Mucosal immunity/defenses:
responses and dysfunction
TUAA0304
Oral serum-derived bovine immunoglobulin (SBI)
administration leads to duodenal gastrointestinal-
associated lymphoid tissue (GALT) CD4 T-lymphocyte
increases and improved small intestinal absorption
function in an 8-week pilot study in patients with
HIV-enteropathy
D.M. Asmuth1, Z.-M. Ma2,3, A. Albanese4, S. Devaraj5, E. Hodzic2,
J.-C. Garcia1, T.H. Knight1, N.M. Flynn1, S. Mann1,4, T. Yotter1,
E. Tsuchida6 and C.J. Miller2,3
1University of California Davis Medical Center, Sacramento,
United States. 2University of California at Davis, Davis, United States.
3Center for Comparative Medicine, Davis, United States. 4Mather
Veterans’s Administration Hospital, Mather, United States.
5University of Texas Children’s Hospital, Houston, United States.
6CARES Clinic, Sacramento, United States
Presenting author email: david.asmuth@ucdmc.ucdavis.edu
Background: HIV-infection leads to GALT CD4 T-cell depletion that
persists despite prolonged antiretroviral therapy (ART). SBI is a
medical food that neutralizes bacterial antigens and reduces gut
inflammation in animal models.
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Methods: Subjects on ART with diarrhea and a thorough negative GI-
workup received SBI (EnteraHealth, Ankeny,IA,USA) 2.5 grams BID for
8 weeks. 4-hour urine disaccharide gut permeability and absorption
test and duodenal biopsies were obtained before and at 8-weeks.
Immunohistochemistry for CD3/CD4 was performed on biopsies and
flow cytometry was performed on duodenal single-cell suspensions
and PBMCs for lymphocyte subsets. Markers of bacterial transloca-
tion and cytokine levels were measured in plasma. Stool was col-
lected for 16S rDNA quantification and sequencing. Median values
(interquartile ranges) and nonparametric analysis are reported.
Results: All 8 subjects experienced resolution of GI-related symp-
toms. D-xylose absorption increased in 7/8 subjects and in those
with improvement, the absorption levels increased from 31.4 mgs
(28.5, 38.8) to 41.5 mgs (33.7, 45.2)(p0.016). Gut permeability was
normal before [0.024% (0.0, 0.048)] and after [0.032% (0.0, 0.047)]
intervention (normalB0.050%). Median duodenal tissue CD4 T-
cell% was unchanged at 16%. Lipopolysaccharide, sCD14, IFN-g, IL-
10, IL-12p70, IL-8, IL-6, and TNF-a were in the normal range before
and unchanged after 8-weeks. Absolute lamina propria CD3/CD4 T-
cell density increased from 199 cells/mm2 (129, 253) to 274 (216,
370)(p0.062) after 8-weeks of SBI [normal values 836 cells/mm2
(474, 1050)]. Previous studies show increases of less than 50 cells/
mm2 after 9 months of ART. Log10 absolute 16S rDNA stool
quantification was unchanged between baseline and week-8 [7.125
cp/gm (6.34, 7.5) to 7.415 (6.4, 7.56)].
Conclusion: SBI improved GI absorption and increased GALT CD4
T-lymphocyte density. Further research is needed to demonstrate
whether alterations in gut microbiota or inflammatory milieu impact
mucosal immunology. Longer studies are needed to examine the
mechanisms of SBI in GALT immune reconstitution and improvement
in HIV enteropathy.
TUAA0305
Improved intestinal immunity and cytotoxic potential of T cells
in interleukin (IL)-21 treated SIV-infected rhesus macaques
S. Pallikkuth1, L. Micci2, Z. Ende2, R. Iriele2, B. Cervasi2, J. Else2,
G. Silvestri2, F. Villinger2, S. Pahwa1 and M. Paiardini2
1University of Miami Miller School of Medicine, Miami,
United States. 2Emory University, Yerkes National Primate Research
Center, Atlanta, United States
Presenting author email: mirko.paiardini@emory.edu
Background: Interleukin (IL)-21 regulates three immunological func-
tions - Th17 cell homeostasis, differentiation of memory B cells and
antibody-secreting plasma cells, and long-term maintenance of
functional CD8T-cells - that are compromised in pathogenic HIV
and SIV infections. Since IL-21 availability is reduced during infection,
we hypothesized that in vivo administration of IL-21 might be
beneficial for HIV infected humans.
Methods: We infected 12 rhesus macaques with SIVmac239 (i.v.), and
then treated 6 of them with rhesus rIL-21-IgFc (50mg/kg, s.c., once
weekly for 5 weeks) during the early infection (from day 14 to 42
post-infection). Effects of IL-21 on viral load, immune activation,
homeostasis of T-cells and their main subsets as well as T-cell
cytotoxic potential have been evaluated in blood and mucosa by q-
PCR, IHC, and flow cytometry up to 6 months post-infection. Mann-
Whitney test and Spearman correlation were used for statistical
analyzes.
Results: IL-21 treatment was safe and did not increase plasma
viral load or systemic immune activation. Compared to untreated
animals, IL-21 treatment resulted in (i) increased expression of
Perforin and GrB in total and virus specific CD8T-cells of various
anatomical sites (PB0.05); and (ii) improved mucosal immunity,
with higher levels of Th17 CD4T-cells (PB0.01) during the
treatment period. Interestingly, improved Th17 homeostasis was
associated with limited proliferation of intestinal CD4and CD8T-
cells (PB0.05) and reduced plasmatic level of LPS (PB0.01) at 6
months post-infection.
Conclusion: IL-21 treatment during acute SIV infection benefi-
cially impacts on the cytotoxic potential of T-cells and intestinal
immunity - including increased homeostasis of Th17 cells, reduced
levels of T-cell activation and limited microbial translocation - without
undesirable effects on viral load. IL-21 should be further explored as a
potential immunomodulator to be used in HIV infection in the context
of ART or as part of new HIV vaccine strategies.
WEPDA0103
Induction and maintenance of HIV-1-specific immune
responses in exposed seronegative (ESN) women of
serodiscordant couples from southern India
S. Solomon1, K.G. Murugavel1, R. Vignesh1, D. Bella1, R. Shoba1,
S. Poongulali1, N. Kumarasamy1, A. Landay2, S.S. Solomon1,3,
C.R. Swathirajan1, P. Balakrishnan1, S. Cu-Uvin4, K.H. Mayer5 and
B.L. Shacklett6
1YRG Centre for AIDS Research and Education (YRG CARE)
Chennai, India. 2Rush University Medical Center, Chicago
United States. 3Johns Hopkins University School of Medicine,
Baltimore, United States. 4Brown University-The Miriam
Hospital, Rhode Island, United States. 5Harvard Medical
School-Beth Israel Deaconess Medical Center/The Fenway Institute,
Boston, United States. 6University of California-Davis, Davis
United States
Background: The majority of new HIV infections are acquired via het-
erosexual transmission. Certain individuals remain seronegative de-
spite repeated high-risk exposure toHIV.The correlates of protection in
exposed seronegative(ESN) individuals remain unclear. The purpose
of this study was to determine the breadth and persistence of HIV-
specific CTL responses in blood and cervical mucosa of ESN women.
Methods: The ESN cohort included 30 female partners of antire-
troviral naı̈ve HIV men. ESN women were followed longitudinally
for 3-6 months. Controls included sero-concordant couples (n17)
and low-risk seronegative women (n30). PBMC and mucosal
mononuclear cells (MMC) from cervical cytobrush were stimu-
lated with HIV Gag and Env (Clade C) peptide pools; IFN-g production
was measured by intracellular cytokine staining. IFN-g production
by0.1% of cells after background subtraction was considered posi-
tive. Samples withB400 total events and/orB10 positive events
were considered equivocal.
Results: At baseline, PBMC from 2 of 30(7%) ESN and MMC from 3 of
17 (18%) ESN responded to stimulation with HIV antigens. During
follow-up, 17 PBMC and 7 MMC samples were analyzed. Of these,
PBMC from 2 ESN(12%) and MMC from 1 ESN(14%) responded to
Gag and/or Env. In HIV women of concordant couples, responses
were detected in 50% of PBMC and 40% of MMC. No responses were
detected in low-risk controls. Median CD4 and plasma viral loads of
male partners of ESN women were 477 cells/mL (range 238-1,090)
and 26,300 copies/mL (range 400-750,000); values for male partners
in sero-concordant couples were 520(range 132-1,321) and 31,850
(range 400-492,000).
Conclusion: These findings confirm that HIV-specific T-cell responses
can be detected in PBMC and MMC from ESN women. These
responses could play a protective role; however, they may simply be
indicative of antigen exposure. A small percentage of ESN women
continued to show positive responses upon longitudinal follow-up,
arguing against a protective role for these responses.
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A12 - Mechanisms of activation /
inflammation and impact in pathogenesis
TUAA0104
Glut1: establishing a new paradigm for HIV-1 infection by
regulating glucose metabolism and activation in CD4 T
cells in HIV-1-positive subjects
C.S. Palmer1,2, J. Zhou1, S. Saleh1, L. Lam1, A. Hearps1,3, A. Maisa1,
C. Pereira1, S. Lewin1,3,4, A. Jaworowski1,3, J.M. McCune5 and
S. Crowe1,3,4
1Burnet Institute, Virology, Melbourne, Australia. 2University of New
South WalesSchool of Medical Sciences, Sydney, Australia. 3Monash
University, Melbourne, Australia. 4Alfred Hospital, Melbourne,
Australia. 5Division of Experimental Medicine, University of
California, San Francisco, School of Medicine, San Francisco,
United States
Presenting author email: c.palmer@unsw.edu.au
Background: A characteristic feature of the early phase of mamma-
lian cells to metabolic stress is an increase in the rate of glucose
uptake and metabolism. Glucose transporter 1 (Glut1) is the major
glucose transporter in T cells and its expression is increased on
CD4T cells during chronic HIV-1 infection in vivo (Palmer et al.,
Abstract 1, IAS, 2012). We therefore seek to determine the impact of
increased Glut1 expression on glucose metabolism in CD4T cells
from HIV-1-infected subjects.
Methods: The cell surface expression of Glut1 and glucose uptake (2-
NBDG) was monitored in CD4T cells from HIV-1 infected treatment
naı̈ve or HIV- controls subjects by flow cytometry. Hexokinase and
glycolytic activity was measured by the intracellular concentrations
of Glucose-6-phosphate (G-6-P) and L-lactate, respectively. Intracel-
lular PTEN, pAkt (T308) and pAkt (S473) levels determined PI3K-
mTOR activity. In vitro HIV-1 infection was performed on PBMCs
activated with anti-CD3/CD28 microbeads and IL-7 and incubated
with the CXCR4-using NL4.3-GFP virus.
Results: Basal glucose uptake, G-6-P, L-lactate, intracellular p-Akt
(T308) and p-Akt (S473) were significantly higher in CD4Glut1
vs CD4Glut1- cells. This corresponded with an overall increased
glucose uptake and glycolysis and lower levels of PTEN expression
in CD4T cells from HIV-1subject vs seronegative individuals.
Anti-CD3/CD28-induced Glut1 expression on CD4 T cells was
sensitive to specific inhibition of the Class1B PI3K-y and mTORC1
pathways which also blocked HIV-1 infection of CD4T cells in
vitro.
Conclusion: CD4T cells from HIV-1 infected patients have increased
glucose uptake and glycolytic activity mediated at least in part by the
PI3k-y-mTORC1 pathway. Increased Glut1 cell surface expression and
glycolysis in CD4T cells may increase their susceptibility to HIV-1
infection and foster their depletion due to hypermetabolism.
Approaches to normalize Glut1 expression or glycolysis in CD4T
cells may offer a platform for interventions to slow HIV-1 disease
progression.
WEAA0204
HIV-induced CD4 T cell depletion: an innate host defense
gone awry?
G. Doitsh, N. Galloway, K. Monroe, Z. Yang, O. Zepeda and
W.C. Greene
The J. David Gladstone Institutes, Virology and Immunology, San
Francisco, United States
Presenting author email: gdoitsh@gladstone.ucsf.edu
Background: Progressive depletion of CD4 T cells is a hallmark of
AIDS yet the underlying mechanism remains poorly understood. In
human lymphoid cultures, most of the dying cells correspond to
abortively infected resting CD4 T cells (Cell 143:789-901,2010). We
have now studied how these cells die.
Methods: Human lymphoid aggregated cultures (HLACs) prepared
with human tonsil and spleen were used to recapitulate many of the
conditions encountered by HIV in vivo. CD4 T cell death is prominent
in HLAC following viral infection.
Results: 95% human lymphoid CD4 T cells that die in HLAC are
abortively, not productively, infected. These nonpermissive resting
cells accumulate incomplete cytosolic viral transcripts that trigger an
innate immune response resulting in interferon-beta production and
activation of caspase-3 and caspase-1. Most cells die as a conse-
quence of caspase-1-mediated pyroptosis, an intensely inflammatory
form of programmed cell death where cytoplasmic contents and
pro-inflammatory cytokines (IL-1b) are released. Unexpectedly,
HIV-induced CD4 T-cell death and release of inflammatory mediators
can be blocked by addition of certain oral sulfonylureas like
glimepiride that inhibit P2X7 ion channels, and are FDA-approved
for the treatment of type II diabetes.
Conclusion: 1. Abortively infected lymphoid CD4 T cells do not die
due to the action of an HIV virulence factor(s), but rather because of
host innate immune response launched against viral DNA produced
in these cells.
2. This response likely evolved to protect the host from spread of
infection, but the involvement of pyroptosis appears to trigger
additional rounds of cell recruitment, infection, cell death, and
inflammation.
3. CD4 T-cell depletion is blocked by P2X7 inhibitors that may
interfere with pyroptosis. Such agents might be clinically useful in
combination with classical antiretrovirals, particularly in HIV-infected
subjects displaying rapid progression of disease or broad drug
resistance.
TUPDA0102
Elite controllers show a unique Tryptophan
immunosuppressive catabolism
M. Patel1, M.-A. Jenabian1,2, B. Lebouché1, M.-J. Brouillette1,3,
C. Tremblay4, I. Kema5, M.-R. Boulassel1,6 and J.-P. Routy1,2,6
1Chronic Viral Diseases Service of the McGill University Health
Centre, Montreal, Canada. 2Research Institute of the McGill
University Health Centre, Montreal, Canada. 3Department of
Psychiatry, Royal Victoria Hospital, McGill University Health Centre,
Montreal, Canada. 4Department of Microbiology and Immunology,
Université de Montréal, Montreal, Canada. 5Department of
Laboratory Medicine, University Medical Center, Groningen,
Netherlands. 6Division of Hematology, McGill University Health
Centre, Montreal, Canada
Presenting author email: jean-pierre.routy@mcgill.ca
Background: Increased Tryptophan (Trp) catabolism into kynurenine
(Kyn) and/or 3-hydroxykynurenine (3OH-kyn) by indoleamine 2,3
dioxygenase (IDO), contributes significantly to the persistent immune
activation during HIV infection and plays a detrimental role in T cell
responses in advanced AIDS. We herein studied Trp catabolism in
elite controllers comparing to other well established groups of HIV
patients with different disease outcomes.
Methods: Plasma samples from elite controllers (EC) (n21),
ART-naive (n96), ART-successfully treated (ST) (n18), and
healthy controls (n51) were collected. All these groups were
standardized for nutritional status (albumin levels and body
mass index). Levels of Trp, Kyn and 3OH-kyn were measured using
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isotope dilution tandem mass spectrometry and the markers of Trp
catabolism (Kyn/Trp and 3OH-kyn/Trp ratios) were correlated to
clinical data.
Results: In ART-naive patients, viral loadwas positively associated with
Kyn, 3OH-kyn levels and the markers of Trp catabolism (pB0.0001).
In addition, these patients presented significantly lower Trp levels
compared to controls (p0.0002) and to ST (p0.042). Accordingly,
both Trp metabolites and Kyn/Trp and 3OH-kyn/Trp ratios were more
enhanced in ART-naive vs ST and controls. EC who spontaneously
control viral load, had the same plasma Trp levels as ART-naive
(mean46.15 vs 46.6 mmol/L, p0.874) but lower than controls and
ST (54.37mmol/L, p0.018 and 52.57mmol/L, p0.138 respectively).
Interestingly, EC had significantly lowered Trp metabolites such as Kyn
and 3OH-kyn levels compared to ART-naive patients (p0.0005 and
p0.025 respectively). In contrast, EC had similar Kyn and 3OH-kyn
levels to Control and STsuggesting a unique Trpmetabolism associated
with suppressed viral replication.
Conclusion: Elite controllers show a unique regulation of immuno-
suppressive Tryptophan catabolism. These findings may be relevant
for HIV viral control and eradication.
A13 - Mechanisms of T cell depletion and
dysfunction
MOAA0205
IL-7 suppresses transcription of the IL-7 receptor alpha
(CD127) gene in human CD8 T cells by inducing the
expression of a STAT5-dependent transcriptional repressor
F. Al-Ghazawi1,2, E. Faller1,2, P. Parmar1,2, J. Kakal1 and
P. MacPherson1,2,3
1University of Ottawa, BiochemistryMicrobiology and Immunology,
Ottawa, Canada. 2Ottawa Hospital Research InstituteChronic and
Infectious Diseases, Ottawa, Canada. 3Ottawa Hospital, Ottawa,
Canada
Presenting author email: feras_ghazawi@hotmail.com
Background: In view of the role interleukin (IL)-7 plays in T-cell
survival, homeostasis and function it is no surprise expression of the
IL-7 receptor alpha-chain (CD127) is tightly regulated. We previously
showed that expression of CD127 is suppressed on CD8 T-cells in
HIV patients and that this suppression is mediated by both IL-7
and the HIV Tat protein. IL-7 down-regulates CD127 transcripts and
surface protein through two distinct mechanisms. In this study we
examine the mechanism by which IL-7 down-regulates the CD127
gene at the level of transcription.
Methods: CD8 T-cells from HIV-negative volunteers were
treated with IL-7 (0.110 ng/ml) in the presence or absence of
various inhibitors. CD127 transcripts were quantified by qPCR.
STAT-5 phosphorylation was measured by flow cytometry. Nuclear
run-on assays were utilized to measure the rate of CD127 gene
transcription. Candidate CD127 repressors were identified using
PCR arrays, qPCR, Western and siRNA-mediated gene knock-down
assays.
Results: IL-7 attenuates levels of CD127 transcripts in CD8 T-cells
in a time- and dose-dependent manner. Both the full-length
transcript and the splice-variant encoding the secreted isoform of
CD127 are suppressed by IL-7. We show by nuclear run-on assay that
IL-7 suppresses the rate of transcription of the CD127 gene and
found no evidence that IL-7 affects the stability of CD127 mRNA.
Further, the suppression of CD127 transcripts is dependent on JAK
kinase activity and phosphorylation of STAT-5 but not STAT-3.
Notably, cycloheximide blocked IL-7’s ability to down-regulate
CD127 transcripts suggesting IL-7 stimulates the de novo synthesis
of a transcriptional repressor which in turn suppresses CD127 gene
transcription. We recently identified several candidate repressors
using PCR arrays and are currently examining their involvement in
the transcriptional suppression by siRNA-mediated knockout experi-
ments.
Conclusion: Upon binding to its receptor, IL-7 activates the JAK/STAT-
5 signaling and induces the expression of a transcriptional repressor
which suppresses CD127 gene transcription.
WEAA0205
Suppressor of cytokine signalling (SOCS) proteins are
induced by IL-7 and the interaction of SOCS proteins with
the IL-7 receptor alpha (CD127) may play a role in regulating
CD127 expression in human CD8 T cells
F. Al-Ghazawi1,2, P. Parmar1,2, E. Faller1,2, S. Sugden1,2, N. Sant3 and
P. MacPherson1,2,3
1University of Ottawa, Biochemistry, Microbiology and Immunology,
Ottawa, Canada. 2Ottawa Hospital Research Institute, Chronic and
Infectious Diseases, Ottawa, Canada. 3Ottawa Hospital, Ottawa,
Canada
Presenting author email: feras_ghazawi@hotmail.com
Background: Interleukin (IL)-7 plays essential roles in T-cell develop-
ment, homeostasis and activation. Disruption of this cytokine
pathway likely contributes to HIV-induced immune deficiency. We
previously showed that IL-7 and the HIV Tat protein reduce the half-
life of the IL-7 receptor alpha-chain (CD127) in human CD8 T-cells but
the mechanism directing CD127 to the proteasome is not yet
understood. In this study we examined roles of SOCS proteins in
regulating CD127 expression.
Methods: CD8 T-cells isolated from healthy HIV-negative volunteers
were treated with IL-7 (0.110 ng/ml) in the presence or absence of
various inhibitors. SOCS1-7 and CIS transcripts were examined by
qPCR and protein expression was measured by Western. The
interaction of SOCS proteins with CD127 was examined by Co-IP.
Surface CD127 protein expression was measured by flow cytometry.
Intracellular localization of SOCS and CD127 protein was examined
by confocal microscopy.
Results: IL-7 induces the expression of SOCS1-3 and CIS transcripts in
CD8 T-cells via the JAK/STAT-5 signaling pathway in a time- and dose-
dependent manner with SOCS2 transcripts increasing 300-fold within
3 hours. While induction of SOCS2 and SOCS3 mRNA was transient,
SOCS1 and CIS transcripts remained elevated over baseline for at
least 48 hours. Western blot analysis confirmed increased protein
expression of the induced SOCS genes. Preliminary data on CD8 T-
cells isolated from HIVpatients indicate that the IL-7-mediated up-
regulation of SOCS transcripts is significantly decreased compared to
healthy controls. IL-7 induces rapid phosphorylation and internaliza-
tion of CD127 followed by proteasomal degradation. By Co-IP
we show SOCS proteins induced by IL-7 physically interact with
CD127 and study their cellular localization by confocal microscopy.
We hypothesize this interaction directs the receptor to the protea-
some.
Conclusion: IL-7 induces the expression of SOCS1-3 and CIS genes
through the JAK/STAT-5 pathway. Through physical interaction with
CD127, SOCS proteins may direct CD127 to the proteasome for
degradation.
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A14 - Pathogenesis in gut, lymphoid
tissues and bone marrow
WEAA0202
Differential SIV infection patterns of lymph node-resident
CD4 T cells distinguishes progressive from nonprogressive
SIV infection
C. Vinton1,2, J. Brenchley1,2, B. Tabb3, X.P. Hao4, V.M. Hirsch2,
M. Paiardini5, J. Lifson3, G. Silvestri5 and J.D. Estes3
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United States. 3National Cancer Institute, National Institutes of
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4National Cancer Institute, National Institutes of Health, Pathology
and Histotechnology Laboratory, Frederick, United States. 5Emory
University, Atlanta, United States
Presenting author email: vintonca@mail.nih.gov
Background: Nonhuman primate natural hosts for simian immuno-
deficiency viruses (SIV) develop a non-resolving chronic SIV infection,
but do not develop AIDS. While several hypotheses, such as down-
modulation of immune activation and differential surface expression
of SIV receptors, have been suggested as putative mechanisms to
explain the nonprogressive nature of SIV infection in natural hosts,
mechanisms underlying high and maintained levels of plasma viremia
without apparent loss of target cells in natural hosts remain unclear.
Methods: Here, we have used flow cytometric sorting, quantitative
real-time PCR, immunohistochemistry, and in situ hybridization to
study viral infectivity and production within subsets of peripheral
blood and lymph node-resident CD4 T cells in cohorts of chronically
SIVsmm-infected sooty mangabeys and SIVsmE53-infected rhesus
macaques.
Results:We find: (1) infection frequencies among PB and LN-resident
CD4 T cells in chronically SIVsmE543-infected RM are significantly
higher than those in SIVsmm-infected SM; (2) differential virus
targeting is observed among anatomical LN niches and among
individual CD4 T cell subsets in SIV-infected RM and SM; (3) lymph
node resident TFH cells are preferentially SIV-infected in RM, but
these cells are not preferentially infected in SM and; (4) infectivity of
central and effector memory CD4 T cells is associated with plasma
viremia in RM while infectivity of only effector memory CD4 T cell
infectivity is associated with plasma viremia in SM.
Conclusion: These data provide mechanistic insights into the
maintenance of immunological function among chronically SIV-
infected natural hosts for SIV, provide an explanation as to how
natural hosts are able to maintain high levels of plasma viremia
without apparent loss of target cells, and may lead to novel gene
therapy interventions to recapitulate the natural host phenotype to
animals that are susceptible to SIV-induced disease.
A23 - Regulation of gene expression and
latency
TUAA0102
Third generation long-read sequencing of HIV-1 transcripts
discloses cell type specific and temporal regulation of RNA
splicing
F. Bushman1, S. Sherrill-Mix1, K. Ocwieja1, R. Mukherjee1, M. Brown2,
J. Chin2, R. Custers-Allen1, P. David3, J. Olson3, K. Travers2 and
E. Schadt2
1University of Pennsylvania School of Medicine, Department of
Microbiology, Philadelphia, United States. 2Pacific Biosciences, Menlo
Park, United States. 3Raindance Technologies, Lexington
United States
Presenting author email: bushman@mail.med.upenn.edu
Background: Transcription of the HIV-1 genome yields an initial pre-
mRNA which undergoes complex alternative splicing to produce over
multiple spliced mRNAs. Analysis of host cell factors important for HIV
replication by genome-wide siRNA screens has emphasized that HIV
replication is extremely sensitive to the complement of available
splicing factors, suggesting that HIVsplicingmay be an attractive target
for therapeutic intervention. Here, we have used single molecule
amplification and third generation sequencing to characterize splice
patterns for the patient isolate HIV89.6 under different conditions.
Methods: We infected HOS cells or primary T-cells and carried out
single molecule PCR in emulsionsto minimize competition among
amplicons. We then used Pacific Biosciences single molecule
sequencing to analyze message populations.
Results: Primary sequence read lengths averaged 1.6 Kb, and 5%
of reads were over 3.8 Kb. Over 100 different messages was
documented, more than doubling the previous number. The HIV
sequence reads confirmed all of the known major splice junctions
and identified new splice junctions, which create new ORFs in the
89.6 isolate. The presence of these new transcripts was confirmed
using RT-PCR. The ORFs encode a novel form of Tat with an altered
carboxy terminus and a Rev-Nef fusion (dubbed ‘‘Ref’’) containing
the amino terminal helix of Rev and the carboxy terminal portion of
Nef. Using this assay, we found that HIV splicing differed between
different cell types, differed between different human donors, and
changes over time after infection.
Conclusion: These data illustrate how the diversity and promiscuity
of splicing in HIV allows the virus to respond to different cellular
environments and provides a continuous supply of evolutionary
novelty that can potentially serve as a substrate for natural selection.
WEPDA0205
HIV-1 Tat protein up-regulates human cellular miRNAs
involved in T cell apoptosis: requirement of Tat second exon
M. Sánchez del Cojo, M.R. López-Huertas, E. Mateos, M. Coiras and
J. Alcamı́
National Centre of Microbiology, Instituto de Salud Carlos III, AIDS
Immunopatology Unit, Majadahonda, Spain
Presenting author email: msdelcojo@isciii.es
Background: HIV-1 infected cells have evolved strategies to delay
apoptosis but the exact mechanism is unknown. One explanation
could be the enhancement of Bcl-2 levels. MicroRNAs (miRNAs) are
small non-coding RNAs that participate in the innate immune
response. Several cellular miRNAs target viral mRNAs, leading to a
decreased viral replication, but viruses may also counteract this
effect. In the case of HIV-1, Tat has been described as an RNAi
suppressor, although this statement remains controversial. To get
better insight into this issue and into the effect of Tat in protection to
apoptosis, we have analyzed the miRNA expression pattern in Jurkat
cells expressing different forms of Tat.
Methods: The miRNA expression profile of Jurkat cells with stable
expression of HIV-1 full-length Tat101 (two-exon protein) or Tat72
(exon 1 isoform) was analyzed with a two color-based array of miRNAs
(Exiqon). Differences in miRNA expression were then confirmed by
qRT-PCR.
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Results: Global down-regulation of cellular miRNAs due to the
expression of Tat was not observed. Instead, several specific miRNAs
were dis-regulated due to the expression of Tat101 or Tat72, although
the expression of the second exon granted a higher modification. We
confirmed that cellular miR-21 and miR-222 were up-regulated in
Jurkat Tat101 cells. miR-21 plays an important role in apoptosis. Since
a higher resistance to FasL-mediated apoptosis was observed in Jurkat
Tat101, we established a correlation between this protection and the
increased levels of Bcl-2 in Jurkat Tat101. Regarding miR-222, it
regulates cell cycle progression. In agreement with this, Jurkat Tat101
cells showed less proliferation capacity than control cells.
Conclusion: HIV-1 Tat does not show a general RNAi suppressor
activity but it increases specifically several human miRNAs, confer-
ring cells protection to apoptosis. This phenomenon was dependent
on the expression of full-length Tat.
A25 - Cellular elements necessary for HIV
replication
TUAA0101
Discovery of novel transcription factors present only in
infected cells
G. Sampey1, R. Van Duyne1,2, I. Guendel1, E. Gregg1, N. Shafagati1,
M. Tyagi1, R. Easely1, Z. Klase3, F. Romerio4, M. Iglesias-Ussel4,
S. Nekhai5, K. Kehn-Hall1 and F. Kashanchi1
1George Mason University, NCBID, Manassas, United States. 2George
Washington University, Washington, United States. 3National
Institutes of Health, Bethesda, United States. 4University of Maryland
School of Medicine, Baltimore, United States. 5Howard University,
Washington, United States
Presenting author email: fkashanc@gmu.edu
Background: Throughout the years many labs have discovered
important factors that contribute to the transcription of HIV-1. Most
of these factors have been well characterized and their significance
has been validated. Some of the critical factors involved in Tat
activated transcription include RNA Pol II (associated with LTR),
chromatin remodeling complexes (i.e. SWI/SNF), acetyltransferases
(i.e. CBP, p300, pCAF), NFkB and components of pTEF-b. Surprisingly,
almost none of the published literature has focused on finding these
factors as complexes from genuine HIV-1 infected cells. Here we
show presence of undiscovered complexes unique to HIV-1 infected
cells which may serve as targets of inhibition.
Methods: We utilized a combination of HIV infected cell lines and
primary latent cells (both T-cells and monocyte/macrophages) to
define changes of protein complexes in infected cells.We utilized large
quantities of infected cell lysates for size-exclusion chromatography to
find novel kinases (i.e. cdk9/T complexes), and chromatin remodeling
complexes, among others in presence of high salt (500 mM).
Results: We found that there are novel cdk9/T complexes ranging
from 2 MDa to 300 KDa present only in T-cells that produce virus.
Other components of the pTEF-b are also examined and found to be
mostly unchanged in infected vs uninfected cells. Other novel
complexes present only in infected cells included kinases for the
NFkB pathway and SWI/SNF proteins. Many of these proteins are
extremely stable and are targets of drug inhibition. Using a small panel
of drugs, we find that many of the kinases utilized for transcription of
HIV-1 have varying IC50s depending on the size of the complex and
their protein partners.
Conclusion: HIV-1 infected cells contain many novel protein com-
plexes that are yet to be discovered. Here we use a simple method of
size exclusion to discover novel complexes that could potentially be
used as targets of inhibition in therapeutics.
A27 - Viral mechanisms of persistence
and latency
MOAA0102
Myeloid dendritic cells and HIV latency in resting T cells
N. Kumar1,2, V. Evans1,2, S. Saleh1,2, C.F. Pereira1,2,3, P. Ellenberg1,2,
P.U. Cameron1,2,4 and S.R. Lewin1,2,4
1Monash University, Department of Medicine, Melbourne, Australia.
2Burnet Institute, Melbourne, Australia. 3Monash University, Monash
Micro Imaging, Melbourne, Australia. 4Alfred Hospital, Infectious
Disease Unit, Melbourne, Australia
Presenting author email: nakum1@student.monash.edu
Background: Latently-infected resting CD4 T-cells are a major
barrier to the eradication of HIV infection. These cells are enriched in
lymphoid tissue compared to blood. We hypothesized that interac-
tions between dendritic cells (DC) and resting CD4 T-cells are
critical for the establishment and maintenance of HIV latency.
Methods: Resting CD4 T-cells labelled with eFluor670 were
cultured alone or with syngeneic DC for 24h prior to infection with
a CCR5-tropic, EGFP-reporter virus. Non-proliferating (eFluor670hi),
non-productively-infected (EGFP-) CD4 T-cells were sorted on day
5 post-infection. Latent infection was re-activated and amplified by
co-culturing sorted cells with mitogen stimulated PBMC.
Results: Infection of resting CD4 T-cells in the presence of myeloid
(m)DC significantly increased latent infection of non-proliferating
CD4 T-cells compared to infection of T-cells cultured alone
(p0.0005, n11). Latent infection was not increased in resting
CD4 T-cells co-cultured with plasmacytoid DC (n11) or monocyte-
derived-dendritic-cells (n 2). Co-culture of mDC with memory
(CD45RO) CD4 T-cells but not naı̈ve (CD45RO-) CD4 T-cells
resulted in latency (n6). eFluor670hiEGFP- CD4 T-cells that had
been co-cultured with mDC showed a significant increase in the
expression of CD69 (p0.01, n8) and PD-1 (p0.007, n10), but
did not express HLA-DR or Ki67. Treatment of the mDC-T-cell
co-cultures with blocking antibodies to the chemokines CCL19 and
CXCL10 (shown to induce latent infection in resting CD4 T-cells); the
chemokine receptor CXCR3; or the adhesion molecule LFA-1 (binds to
ICAM) led to no changes in the frequency of latently-infected CD4 T-
cells (n5).When mDC-T-cell contact was prevented using transwells
the number of latently-infected CD4 T-cells was reduced (n3).
Conclusion: mDC play a key role in the establishment and/or
maintenance of HIV latency in resting memory CD4 T-cells. Our
results suggest this is likely to be mediated through DC-T-cell contact
via alternative pathways to ICAM-LFA-1 binding.
TUAA0201
Unique regulatory mechanisms of CNS-derived HIV-1 LTRs
associated with latency
L. Gray1,2, D. Cowley1,3, E. Crespan1, C. Welsh1,4, C. Mackenzie1,5,
P. Gorry1,3,6, S. Wesselingh1,7 and M. Churchill1,3,4
1Burnet Institute, Centre for Virology, Melbourne, Australia. 2Monash
University, Department of Biochemistry and Molecular Biology,
Clayton, Australia. 3Monash University, Department of Medicine,
Clayton, Australia. 4Monash University, Department of Microbiology,
Clayton, Australia. 5Monash University, Department of Immunology,
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Microbiology and Immunology, Melbourne, Australia. 7South
Australian Health and Medical Research Institute, Adelaide, Australia
Presenting author email: lachlang@burnet.edu.au
Background: HIV-1 penetrates the central nervous system (CNS)
during early infection, establishing a viral reservoir. While macro-
phages and microglia represent the sites of productive HIV-1
infection, astrocytes undergo a restricted/latent infection. We
recently demonstrated that astrocytes are extensively infected and
may therefore constitute a significant potential reservoir of HIV-1
within the CNS. Here, we analyzed HIV-1 promoters (LTR) from
matched CNS and non-CNS compartments to determine their role in
virus restriction within CNS-derived cells. Determining the regulatory
mechanisms of CNS-derived LTRs is essential to understanding the
CNS as a HIV-1 viral reservoir, and in developing strategies aimed at
HIV-1 eradication.
Methods: HIV-1 LTR sequences from a cohort of HIV-1 autopsy
subjects consisting of matched CNS- and non-CNS-derived isolates
were examined and their activity was determined in T-cells and SVG
astrocyte cells. Electrophoretic mobility shift assays (EMSA) were
used to analyze transcription factor binding activity within the core
and basal promoter regions of the LTR.
Results: CNS-derived LTRs demonstrated restricted basal transcrip-
tional activity in both T-cells and SVG cells, and non-CNS-derived
LTRs showed decreased activity in SVG cells. Restricted basal
activity mapped to the three Sp binding motifs, previously shown
to be essential for both Tat-independent and Tat-dependent activa-
tion of the LTR in T-cells. Further repression in astrocytes
was observed due to elevated levels of the repressor Sp3 in SVG
cells.
Conclusion: The reduced transcriptional activity observed for CNS-
derived HIV-1 promoters was found to correlate with a reduction in
Sp1 binding, which mapped to mutations within the core Sp binding
motif. Transcriptional activity in SVG cells was further regulated by
Sp3, which outcompeted Sp1 for Sp-motif binding. These data
suggest that CNS-derived viruses have a reduced capacity to initiate
viral transcription in astrocytes and highlights that unique transcrip-
tional mechanisms exist within the CNS, ultimately affecting the fate
of viral infection and the development of latency.
TUAA0202
Complete transcriptome analysis of latently infected CD4
T cells
M. Iglesias-Ussel1, L. Marchionni2 and F. Romerio1
1University of Maryland School of Medicine, Institute of Human
Virology, Baltimore, United States. 2Johns Hopkins University, Sidney
Kimmel Comprehensive Cancer Center, Baltimore, United States
Presenting author email: fromerio@ihv.umaryland.edu
Background: Latent reservoirs of HIV-1 consist of cells harboring
dormant, stably integrated viral genomes that can be reactivated
after cell stimulation. Latent HIV-1 evades immune responses and
resists anti-retroviral therapy. CD4 T cells are the major reservoir of
latent HIV-1. These cells are very rare and lack distinctive markers,
which has hindered their characterization.
Methods: We developed an in vitro model suitable to investigate
HIV-1 latency in CD4 T cells. In our system CD4 T cells are
activated with dendritic cells and antigen, infected in vitro with HIV-
1, and then brought back to quiescence through a resting phase in
the presence of interleukin-7. During the resting phase, the latently
infected cells generated with our system lack expression of activation
markers; do not undergo cellular proliferation and do not sustain
viral replication. We sorted latently infected and uninfected cells
from the same cell culture at the end of the resting phase, and
profiled their entire transcriptome.
Results: The results of this microarray analysis revealed profound
differences between latently infected and uninfected cells derived
from the same culture. First, a number of genes involved in all major
cellular metabolic pathways are down-modulated in latently infected
cells. Second, several messengers involved in gene expression
(including chromatin organization, transcription, translation, post-
translational modification, transport and assembly) are also down-
regulated in latently infected cells. Third, genes involved in signal
transduction, cell activation, cell proliferation and cell cycle progres-
sion are down-modulated in latently infected cells. Finally, several
genes encoding cell surface molecules are differently expressed in
latently infected vs. uninfected cells.
Conclusion: The establishment of HIV-1 latency does not simply
entail suppression of HIV-1 expression, and the return to cell
quiescence. Rather, HIV-1 appears to exploit and/or promote
suppression of all cellular functions, leading to cell quiescence and
viral latency. These results may have therapeutic implication for viral
eradication.
TUAA0204
Epigenetic modifications of HIV proviral LTRs: potential
targets for cure
S. Weber1, H. Burger2, K. Kemal2, B. Weiser2, K. Korn1, K. Anastos3
and W. Doerfler1
1Erlangen University, Institute for Virology, Erlangen, Germany.
2Wadsworth Center, New York State Dept. of Health, Albany,
United States. 3Albert Einstein College of Medicine/ Montefiore
Medical Center, New York, United States
Background: HIV-1 cure remains elusive despite HAART due to the
reservoirs of proviral DNA integrated into the human genome. Efforts
to cure HIV-1 therefore need to aim at eliminating proviral DNA from
cellular reservoirs. The first epigenetic signal identified in virus
infected and uninfected cells has been promoter methylation.
Compelling evidence confirms that specific promoter methylation
can lead to gene silencing. Previous studies have examined HIV-1
epigenetics mostly in vitro.
Methods: We determined methylation patterns in HIV-1 proviral
genomes from PBMCs obtained from 21 individuals with a spectrum
of disease progression. The CpGs in the long terminal repeats (LTRs)
of proviral DNA were investigated by bisulfite sequencing in up to
85 genomic variants per individual. This approach facilitates the
study of the full range of CpG methylation and sequence variability
of HIV-1 proviruses under conditions of natural selection in human
populations.
Results: In patients with advanced disease, the HIV-1 proviruses
remained essentially unmethylated in their LTRs. In one long-term
nonprogressor, the percentage of methylated proviruses varied
from 077% at different times after infection. More important and
unexpected was the detection of three specific LTR-located CpG
dinucleotides that had been selectively mutated to TpAs in20 out
of the 32 samples analyzed. Comparison to 11 HIV-1 LTR sequences
in the Los Alamos HIV database demonstrated that mutations in
the sites identified by our study occurred more frequently than
at other locations, although the mutations were different from
TpAs.
Conclusion: These specific CpGs, possibly including their abutting
sequences, might indicate weak spots in the proviral genomes whose
sacrifice by mutation to TpAs could enhance the HIV-1 potential for
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long-term proviral survival. These data suggest that the sites of the
mutated CpGs occurring at conserved sites may serve as potential




Unique integration patterns: in vitro model of HIV latency
S. Saleh1,2, D. Vatakis3, P. Cameron1,2,4, A. Harman5, A. Cunningham5
and S. Lewin1,2,4
1Monash University, Medicine, Melbourne, Australia. 2Burnet
Institute, Melbourne, Australia. 3University of California at Los
Angeles, Medicine, Los Angeles, United States. 4Infectious Diseases
Unit, Alfred Hospital, Melbourne, Australia. 5Westmead Millenium
Institute, Sydney, Australia
Presenting author email: suha.saleh@med.monash.edu.au
Background: We have demonstrated that HIV latency can be
established in resting CD4 T-cells infected after incubation with
the CCR7 ligand, CCL19. The aim of this study was to identify the sites
of viral integration in this model and to determine the relationship of
integration sites to transcription factor binding sites and cellular
gene expression.
Methods: Resting CD4 T-cells were incubated with either IL2/PHA,
CCL19, or in media alone (unactivated). After 2 days, cells were
infected with NL4.3 and the presence of integrated DNA was
confirmed at day 4. Total cellular DNA was purified and provirus-
host junctions cloned and sequenced and mapped on the human
genome using the UCSC Genome Browser. Gene expression in each
cell type was determined using Illumina microarrays. Comparisons
were made between these in vitro conditions and CD4 T-cells from
HIV-infected patients on antiretroviral therapy (ART). Gene ontology
was analysed using ClueGo.
Results: We identified unique integration sites in infected CCL19-
treated (n247), IL2/PHA (n432) and unactivated (n133) T-
cells. Integration occurred in transcriptionally active genes and most
were involved in cellular housekeeping and cell signalling pathways.
Integration sites were a similar distance from CpG islands, CTCF, pol II
and histone methylation and acetylation sites. Compared to IL2/PHA-
activated and unactivated cells, integration in CCL19-treated cells
was further away from regions with high transcriptional activity
(including transcriptional start sites (TSS); (pB 0.0001)) and closer to
Long Interspersed Nuclear Elements (pB 0.0001), H4K20me3 (pB
0.0001) (a methylation site mapped to heterochromatin) and
H4R3me2 (pB 0.0001; involved in priming gene expression).
CCL19 treated cells and patient derived cells were similar in some
but not all integration site patterns.
Conclusion: HIV integration occurred in transcriptionally active genes
in all culture conditions although integration patterns in CCL19-
treated latently infected cells were distinct. The significance of
unique integration site selection in the setting of latency warrant
further investigation.
THAA0104
SIVagm infection of rhesus macaques: a model of functional
cure with persistent reservoirs of replication-competent
virus
D. Ma1, A. Cillo2, C.L. Xu1, J. Kristoff1, J. Fang1, G. Haret-Richter1,
J. Mellors2, I. Pandrea1 and C. Apetrei1
1University of Pittsburgh, Center for Vaccine Research, Pittsburgh,
United States. 2University of Pittsburgh, Division of Infectious
Diseases, Department of Medicine, Pittsburgh, United States
Presenting author email: apetreic@pitt.edu
Background: SIVagm infection of rhesus macaques (RMs) provides a
model of functional cure: initial high level viremia (108 copies/ml)
and massive mucosal CD4 T cell depletion are followed by durable
control of SIVagm replication, complete recovery of CD4 T cells,
normalization of T-cell activation and seroreversion. The advantage of
this model is that the functional cure occurs in all SIVagm-infected
RMs. Immune control of SIVagm replication can be temporary
reversed by experimental CD8-cell depletion.
Methods: Our objectives were to further characterize the RM/
SIVagm model of functional cure by: (i) assessing the level of
persistent chronic SIVagm viremia using qPCR with single copy
sensitivity (SCA); (ii) determining whether rebounding virus after
CD8-cell depletion is replication-competent by inoculation of unin-
fected RMs; and (iii) characterizing the diversity of rebounding virus
using single genome sequencing (SGS).
Results: SCA revealed low level viremia, averaging 20 copies/ml
(range 1030), in RMs 9 month after viremia became undetectable
by conventional qPCR. Inoculation of new RMs with plasma collected
during virus rebound after CD8 cell depletion resulted in peak
viremia of 108109 SIVagm RNA copies/ml, followed by control of
viremia with kinetics similar to that following infection with high titer
SIVagm stock virus. SGS of rebound plasma virus after CD8 cell
depletion revealed sequence homogeneity consistent with clonality.
Rebound virus was genetically similar to unpassaged SIVagm used to
infect RMs, suggesting that the viral reservoirs that were the source
of the rebounding virus were seeded early after infection.
Conclusion: These findings further validate SIVagm-infected RMs as a
model of functional cure of replication-competent retrovirus infec-
tion. Deciphering the mechanisms of control may identify new
strategies to achieve functional cure. This model is well suited to
assess new therapeutic strategies to deplete viral reservoirs without
the complexity of multidrug antiretroviral therapy.
MOLBA01
Unintegrated HIV-1 generates an inducible reservoir of
replication competent virus in nonproliferating CD4 T cells
B. Trinité, E. Ohlson, S. Rana, J. Alster and D.N. Levy
New York University College of Dentistry, Basic Science, New York,
United States
Background: Integration into host cell chromosomal DNA is con-
sidered an essential step in the replication of retroviruses, yet HIV-1
replication in vivo or in vitro generates one to two orders of
magnitude more copies of unintegrated viral DNA (uDNA) than
successfully integrated proviruses (iDNA). These extrachromosomal
species are reported to possess limited capacity for gene expression
and to be a replicative dead end. Resting CD4 cells are the major
targets of early infection following mucosal transmission, and resting
memory CD4 T cells constitute the major reservoir of latent
infection. The cytokine environment in mucosal and lymphoid
compartments facilitates HIV-1 infection of CD4 T cells in the
absence of TCR mediated activation.
Methods: We employed a combination of HIV-1 reporter viruses,
flow cytometry and quantitative PCR to analyze HIV-1 early and late
gene expression and virus production in purified peripheral blood
CD4 T cells.
Results: We find that resting CD4 T cells rendered permissive
to HIV-1 replication by cytokines IL-2, IL-4, IL-7 or IL-15 provide a
reservoir for the persistence of unintegrated HIV-1 DNA. Nonprolifer-
ating cells containing uDNA could generate de novo HIV-1 and trans-
mit virus efficiently to uninfected cells, resulting in recombination
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between viruses. uDNA generated an order of magnitude less virus
than integrated proviruses, but cells generating virus from uDNA
survived and produced virus longer. Vpr packaged in virions was
necessary for initial gene expression from uDNA. Subsequent T cell
receptor/coreceptor-mediated activation substantially increased
early viral gene expression from uDNA, but an increase in virus
production was observed only when activation-induced cell prolifera-
tion was inhibited by de novo Vpr generated from the uDNA template.
Activation through the T cell receptor or HDAC inhibitors in
combination with Prostratin efficiently activated latent uDNA several
weeks after infection of resting T cells.
Conclusion: We propose unintegrated HIV-1 as a potential reservoir
of inducible virus.
WEPDA0202
Role of UHRF1 in transcriptional regulation and
maintenance of HIV-1 latency
A.F.B. Victoriano, Y. Hibi, N. Tan Gana, K. Asamitsu and T. Okamoto
Nagoya City University Graduate School for Medical Sciences,
Department of Molecular and Cellular Biology, Nagoya, Japan
Presenting author email: rency@med.nagoya-cu.ac.jp
Background: A thorough understanding of the molecular mechan-
isms governing HIV-1 latency is essential in the development of
rational therapeutics for the eradication of the virus. Evidence is
accumulating that histone methylation regulates HIV latency. The
multi-domain protein UHRF1 (ubiquitin-like, containing PHD and
RING finger domains 1), a key epigenetic regulator for maintaining
DNA methylation patterns, has also been reported to interact with
histone 3 lysine 9 methylated histones. This study investigates the
role of UHRF1 in the transcriptional silencing of latent HIV-1 provirus.
Methods: 293T cells were co-transfected with wild type HIV-1 long
terminal repeat (LTR) and either with constructs encoding wild type
or mutant forms of human UHRF1, treated with tumor necrosis
factor alpha (TNF-a) and the promoter activity was determined by
the dual luciferase assay. The presence of UHRF1 at the LTR was
assessed by chromatin immunoprecipitation assay using sheared
chromatin lysates from latently infected cells, ACH-2 and J-Lat 6.3.
Small interfering RNA (siRNA) experiments were conducted using
TZM-bl cells, which contain a chromatin-integrated HIV-1 LTR, to
confirm the influence of UHRF1 on the HIV-1 LTR.
Results: We observed that UHRF1 inhibited both basal and the
induced HIV-1 gene expression by TNF-a. Chromatin immunopreci-
pitation assay revealed the presence of UHRF1 at the vicinity of the
HIV-1 LTR and UHRF1 occupancy was reduced upon activation.
Meanwhile, knockdown of UHRF1 expression modestly increased
basal LTR activity.
Conclusion: Results suggest that UHRF1 contributes to the transcrip-
tional silencing of latent HIV-1 provirus and further elucidate the
underlying molecular mechanisms that maintain latency.
WEPDA0203
Modeling HIV latency using the humanized BLT mouse
M. Marsden, M. Kovochich, N. Suree, S. Shimizu, R. Mehta,
R. Cortado, G. Bristol, D.S. An and J. Zack
UCLA, Los Angeles, United States
Presenting author email: mmarsden@ucla.edu
Background: Replication-competent HIV persists in patients who are
treated with highly active antiretroviral therapy (HAART). One
significant reservoir of this persistent virus is within rare latently
infected CD4 T cells. However, the infrequent nature of these cells
makes them challenging to study directly in infected patients, and
clinical attempts to completely eliminate this viral reservoir have not
been successful. Therefore improved models for HIV latency and
eradication strategies are needed. The humanized bone marrow-liver-
thymus (BLT) mouse provides robust multi-lineage immune recon-
stitutionwith human cells.When infectedwith HIV, thesemice can also
serve as an in vivo model for investigating HIV latency.
Methods: BLT mice were infected with HIV and assessed for the
presence of latently-infected cells. Cells were stimulated ex vivo with
a variety of canonical and novel latency activators. Infected mice
were also treated with HAART and then assessed for the presence of
activation-inducible virus.
Results: Up to 3% percent of human cells in spleen, peripheral blood,
and thymus/liver implants in HIV-infected BLT mice harbored latent
HIV. This virus was integrated, activation-inducible, and replication
competent. The latently-infected cells were also responsive to
stimulation with protein kinase C activators and latency-activating
nanoparticles. Furthermore, activation-inducible virus was detect-
able in HAART-treated mice, although at lower frequencies than in
untreated mice.
Conclusion: The humanized BLT mouse provides a versatile system
for ex vivo and in vivo investigation of HIV latency.
WEPDA0204
Maraviroc (MVC) can activate NFkB in resting CD4 T cells of
patients infected with R5 or D/M HIV-1
N. Madrid-Elena, B. Hernandez-Novoa, M. Lamas, L. Garcia-Bermejo
and S. Moreno
Hospital Ramon y Cajal, Madrid, Spain
Presenting author email: nadiapatricia.madrid@salud.madrid.org
Background: In a previous ART intensification study with MVC we
detected episomal 2-LTR-DNA in all patients at week 24, while
undetectable at baseline (Gutierrez C, et al. PLoS ONE, 2011). A
residual agonistic effect of MVC on CCR5 receptor through calcium
flux has been discarded. Activation of CCR5 intracellular signaling
pathways leading to transcription factors activation, including NFkB,
could promote HIV-1 transcription in resting CD4 T cells. We aimed to
study if MVC could trigger this effect.
Methods: TROPISMVC (NCT01060618) is a clinical trial of 10 days
MVC monotherapy in naı̈ve HIV-1-infected patients. Blood samples
were drawn at baseline, after 10 days of MVC and 18 days after MVC
withdrawal (day 28). PBMCs were isolated from nine patients,
bearing CCR5 (n6) and D/M (n3) tropic viruses. Resting CD4 T
cells were separated by MACS
†
Technology and aliquots of 5 million
cells were frozen. Nuclear proteins were obtained using the Actif
Motif Nuclear Extract Kit. NFkB activation was detected by ELISA
plates coated with oligonucleotides mimicking the specific consensus
binding sites (TransAMTM NFkB family, Actif Motif), following
the manufacturer’s instructions. NFkB activity was estimated mea-
suring target genes’ expression by real-time PCR of the extracted
RNA.
Results: NFkB activity was detected in 4/6 patients with R5 tropic
viruses and in 2/3 patients with D/M tropic viruses; results expressed
in fold change (FC) compared to baseline according to HIV-1 tropism.
The presence of MVC increased NFkB activity consistently, as
summarized in the following table. Upregulation of at least one
NFkB targeted gene was observed in all but one cases with available
RNA sample.
Conclusion: MVC can activate NFkB, and the expression of targeted
genes, in resting CD4 T cells from HIV-infected patients regardless of
the viral tropism. Through this pathway, MVC could trigger HIV-1
transcription in resting cells thus accelerating the decay of the HIV-1
cell reservoir.
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CXCR4-tropism is associated with the preferential
establishment of an HIV-reservoir in naı̈ve CD4 T cells
among HIV-positive Ugandan children receiving
antiretroviral therapy
T. Ruel1, J. Achan2, W. Huang3, H. Cao4, P. Li4, L.A. Eller5, M. Killian4,
E. Sinclair4, E. Charlebois4, D.V. Havlir4 and J. Wong4
1University of Calfornia at San Francisco, Department of Pediatrics,
San Francisco, United States. 2Makerere University College of Health
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United States
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Background: Children have large populations of naive CD4 T-cells
that characteristically express high levels of CXCR4 and low levels of
CCR5, compared to memory CD4 T-cells. We hypothesized that
HIV Ugandan children infected with CXCR4-tropic virus would
exhibit larger HIV-DNA reservoirs in naı̈ve CD4 T-cells, compared to
children infected with CCR5-tropic (R5) virus.
Methods: Cryopreserved PBMC from a convenience sample of 12
HIV Ugandan children receiving antiretroviral therapy (ART) with
undetectable plasma HIV-RNA (B 400 copies/ml, Amplicor, Roche)
were sorted into naı̈ve (CD27CD45RA) and memory (CD27-
CD45 and CD45-CD279) CD3CD4 T-cells. HIV-DNA levels
were determined using a Taqman assay targeting gag, normalized to
cellular-DNA content (tert, ABI). Co-receptor tropism was determined
using a commercial phenotypic assay (Trophile, Monogram). We
calculated 1) the ratio of the prevalence of infection (copies per 106
cells) in naı̈ve to the prevalence in memory CD4 T-cells and 2) the
proportion of the total peripheral CD4 T-cell HIV-reservoir that is
contained in naı̈ve CD4 T-cells, and compared them between
children with R5- and dual/mixed(CXCR4/CCR5, DM)-tropic virus
using non-parametric statistics.
Results: Median age was 4.9 (interquartile range 3.5-8.1) years,
CD4T-cell number 743 cells/ul (565-1089), CD4 T-cell percentage
25 (21-29), and ART duration 95 days (95-147), with 6 subjects each
with HIV-envelope-subtypes A and D. R5 virus was identified in 8 and
DM virus in 4 children.
Conclusion: In ART-treated adults, the vast majority of persistently
infected CD4 T-cells are memory cells. By contrast, we found that a
significant proportion of the reservoir resides in the naı̈ve CD4 T-
cells among Ugandan HIV ART-treated children. Infection with DM
virus was associated with preferential naı̈ve T-cell infection. In
developing strategies to eradicate HIV, it will be important to take
into account the high levels of naı̈ve T-cell infection in children,
particularly among those with DM virus.
A28 - Mechanisms of eradication
THAA0101
Long-term reduction in peripheral blood HIV-1 reservoirs
following reduced-intensity conditioning allogeneic stem
cell transplantation in two HIV-positive individuals
T.J. Henrich1,2, G. Sciaranghella3, J.Z. Li1,2, S. Gallien4, V. Ho2,5,
A.S. Lacasce2,5 and D.R. Kuritzkes1,2
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Medical School, Boston, United States. 3Ragon Institute of MGH, MIT
and Harvard, Boston, United States. 4Hopital Saint-Louis, Paris,
France. 5Dana-Farber Cancer Institute, Boston, United States
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Background: Functional HIV-1 cure has been described in the setting
of myeloablative allogeneic stem cell transplant (alloSCT) with
ccr5^32/ ccr5^32 donor cells, but the effects of alloSCT on viral
reservoirs are largely unknown. We studied the longitudinal effects
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R5 2,962 (12910,668) 9,931 (103711,808) 0.7 (0.24.3) 53% (25%80%)
DM 14,733 (1,344135,120) 930 (15129,702) 8.9 (6.613.0) 92% (88%95%)
P-value* 0.31 0.61 0.04 0.07
* Comparing R5 to DM with Kruskal-Wallis Test.
HIV-Reservoir by CCR5/DM Tropism.
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of reduced-intensity conditioning (RIC) alloSCT on HIV-1 peripheral
blood reservoirs in two infected male patients with hematologic
malignancies who previously underwent autologous SCT.
Methods: Analysis of peripheral HIV-1 reservoirs was performed on
banked samples (1 pre- and 3 post-RIC-AlloSCT) for both patients,
including: 1) quantification of HIV-1 DNA from peripheral blood
mononuclear cells (PBMCs), 2) quantification of 2-LTR circles from
PBMC episomal DNA, 3) full-length envelope amplification and
phenotypic coreceptor usage prediction from proviral DNA, 4)
quantification of plasma viremia by a single-copy assay, 5) flow
cytometric characterization of lymphocyte subsets and coreceptor
expression, and 6) CCR5 genotyping.
Results: No HIV-1 DNA was detected 8 to 17 months after alloSCT
in PBMC from both patients despite presence of modest levels of
total PBMC-associated HIV-1 DNA prior to and 2-3 months after
SCT (87271 copies/106 PBMCs). 2-LTR circles were not detected
at any time-point despite excellent recovery of episomal mito-
chondrial DNA. Both patients were heterozygous for ccr5^32
mutation prior to transplant; a transient reduction in CXCR4
expression was observed following transplant. Pseudoviruses
incorporating envelopes from early time-points used predomi-
nately CCR5 for entry. Both patients remained virologically
suppressed on ART, but were either started on prednisone or
continued on tacrolimus/sirolimus immunosuppressive therapy for
chronic graft-versus-host disease (GVHD) near the time of loss of
HIV-1 reservoir detection.
Conclusion: PBMC HIV-1 DNA became undetectable 8 months after
RIC-alloSCT. This finding may be due to a dilutional effect of donor
cell engraftment in the setting of protective ART, the additive effect
of cytotoxic therapies, and/or GVHD. Confirmation of results by
sampling large-volume blood collections and other tissue compart-
ments is warranted.
MOLBA02
Evaluation of treatment with the histone deacetylase
inhibitor vorinostat (suberoylanilide hydroxamic acid;
SAHA) in antiretroviral drug treated, SIVmac239-infected
rhesus macaques
J. Lifson1, G. Del Prete1, R. Kiser1, C.M. Trubey1, J. Smedley2,
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Background: Nonhuman primate (NHP) models are needed for
evaluation of proposed but unproven, and potentially dangerous
strategies targeting residual virus and latent reservoirs in AIDS virus-
infected subjects receiving suppressive antiretroviral drug treat-
ment (ART), but such models have proven challenging to develop.
Methods: We treated a cohort of 6 Indian rhesus macaques with
a novel three class (NRTI, PI, IN-STI) six drug (PMPA/FTC/DRV-RTV/
L-870812/L-870564) ART regimen beginning at 4 weeks post-
infection with SIVmac239. Peripheral blood CD4 T cells from ART-
treated animals with suppressed viremia were evaluated ex vivo
for responses to SAHA, including changes in histone acetylation
patterns and induction of expression of SIV. Beginning approximately
26 weeks post infection, animals received four 21 day courses of
daily treatment with SAHA, with each course of SAHA separated by
an approximately 3 week interval, with continuous ART throughout
and longitudinal sampling of blood and lymph nodes for immuno-
logical, virological, and pharmacodynamic evaluations. Animals were
euthanized and necropsied after the final SAHA dose, while still on
ART, and tissues studied virologically.
Results: The ART regimen was feasible, safe and well tolerated
over one year of treatment and allowed suppression of plasma
viremia toB30 copy Eq/mL. Ex vivo SAHA treatment of CD4 T cells
from ART-suppressed macaques increased histone acetylation and
induced SIV expression. SAHA treatment of macaques was safe and
well tolerated, and induced measurable in vivo changes in histone
acetylation in CD4 T cells but did not reproducibly impact plasma
viremia. Analysis of cell associated viral DNA and RNA levels from
blood and tissues is in progress and will be presented.
Conclusion: This study demonstrates the feasibility of developing
and applying NHP models for studying AIDS virus reservoirs and
eradication strategies, along with the in vivo safety of SAHA treat-
ment at pharmacologically active doses.
THPDA0201
The cure of the ’Berlin patient’: why did pre-existing X4-
variants not emergence after allogeneic CCR5-D32 SCT?
J. Symons1, S. Deeks2, G. Hutter3, A. Wensing1, J. Martin2, P. van
Ham1, L. Vandekerckhove4 and M. Nijhuis1
1University Medical Center Utrecht, Department of Virology, Utrecht,
Netherlands. 2University of California, Department of Medicine
San Francisco, United States. 3Heidelberg University, Institute of
Transfusion Medicine and Immunology, Mannheim, Germany
Patient
Sample Collection Time
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Quantification of Peripheral Blood HIV Reservoirs.
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Background: The ‘‘Berlin patient’’ is the first patient functionally
cured of HIV. He received stem cell transplantation from a
homozygote CCR5-D32 donor. The reconstituted CD4 T-cell popula-
tion should be susceptible to infection with CXCR4-using viruses.
According to gp120-V3 deep sequencing analysis of plasma-derived
variants present before transplantation, the patient harbored a
minority (2.9%) of viruses predicted to be CXCR4-tropic (geno2phe-
nocoreceptor FPR 10%). It remains puzzling why these variants failed to
emerge post-transplant. We hypothesize that these CXCR4-predicted
variants depend on CCR5 for replication.
Methods: Patient-derived viral constructs were generated by cloning
V3-sequences of the CXCR4-predicted viruses (pX1-pX7) and the
dominant CCR5-predicted strain (pR5) into HXB2-DV3. As controls
V3-sequences of HXB2 (cHXB2; CXCR4-tropic) and BaL (cBaL; CCR5-
tropic) were cloned. Co-receptor preference was investigated in U-
373-MAGI-cells expressing CD4CCR5 or CD4CXCR4, PBMCs
from healthy donors and patient-derived post-transplant CCR5-D32
PBMCs.
Results: Three pre-transplant CXCR4-predicted strains had an amino
acid substitution in the V3 glycosylation-motif and one had a lysine
at position 25, all associated with CXCR4-tropism. Five of the 7 viral
clones were infectious. As expected cHXB2 infected CD4CXCR4-
MAGI-cells and was inhibited by AMD-3100 (CXCR4-inhibitor) in
donor PBMCs. Remarkably, the CXCR4-predicted viruses (FPR 2.7
9.3) depended on CCR5 for replication in MAGI-cells and were
inhibited by maraviroc (CCR5-inhibitor) in donor PBMCs similar to
pR5 and cBaL. As an ultimate proof it was shown that CXCR4-
predicted strains could not replicate in the post-transplant derived
CCR5-D32 PBMCs, whereas cHXB2 replication was observed.
Conclusion: The minority population of CXCR4-predicted viral strains
which the patient harbored pre-transplant were fully dependent on
CCR5 for replication in vitro. This could explain lack of rebound after
treatment discontinuation. This provides a strong rationale for the
further development of CCR5-targeted gene therapy and suggests
that successful reconstitution of CCR5-depleted immune system may
work, even if there is some evidence of CXCR4-predicted variants.
A29 - Tissue reservoirs
THAA0102
Viral tissue reservoirs are determined early and little viral
RNA is detected during suppression by three or four drug
regimens in the macaque model
C. Kline1, J. Ndjomou1, T. Franks1, R. Kiser2, V. Coalter2, M. Piatak, Jr2,
J. Estes2, J. Mellors1, J. Lifson2 and Z. Ambrose1
1University of Pittsburgh School of Medicine, Medicine, Pittsburgh,
United States. 2SAIC-Frederick, Inc., NCI Frederick, AIDS and Cancer
Virus Program, Frederick, United States
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Background: Although HIV-infected individuals can suppress plasma
viremia to undetectable levels with antiretroviral therapy, infected
cells remain in the body and can contribute to viremia when therapy
is discontinued. Macaque models allow investigators to more easily
characterize viral reservoirs.
Methods: Twelve male macaques were infected with RT-SHIV, an SIV
virus containing HIV-1 reverse transcriptase, and monitored for
plasma viremia and CD4 counts. After 10-14 weeks post-infection,
6 animals were not treated and 6 animals were treated for 1720
weeks with 3 drugs (tenofovir, lamivudine, and efavirenz) or 4 drugs
(tenofovir, lamivudine, efavirenz, and an integrase inhibitor). Viral
RNA and viral DNA were measured longitudinally in the blood and
at necropsy in over 20 different tissues by quantitative PCR and
normalized for cellular RNA and DNA.
Results: In untreated and treated animals, RT-SHIV DNA was highest
in lymphoid and gastrointestinal tissues and very low to absent in the
brain, genital tract, and kidney. The amount of viral DNA detected in
multiple lymphoid tissues correlated with the level of plasma viremia
1 week post-infection. RT-SHIV RNA was abundant in the lymphoid
tissues of untreated macaques with detectable viremia, but was
detected variably in different regions of the gastrointestinal tract.
Little or no viral RNA was detected in the tissues from animals after
17-20 weeks of therapy. There was no obvious difference in RT-SHIV
RNA levels between animals treated with 3 or 4 drugs.
Conclusion: Our results suggest that the majority of virally-infected
cells are located in lymphoid tissues with variable levels in the
gastrointestinal tract. The number of infected cells in these reservoirs
correlates with viremia one week after infection, suggesting that viral
reservoirs are seeded within days of infection. Little viral RNA is
evident in tissue after suppressive therapy with either 3 or 4
antiretroviral drugs.
THAA0105
Characterization of persistent HIV-1 in a broad spectrum of
CD4 T cells isolated from peripheral blood and gut
associated lymphoid tissue from patients on long-term
suppressive therapy
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Background: The role of ongoing virus replication in HIV persistence
during long-term antiretroviral therapy is unknown. Since residual
replication should result in detectable evolution, we investigated the
degree of sequence evolution in blood-derived and rectal tissue-
derived CD4 T cells.
Methods: Using single-genome and single-proviral sequencing tech-
niques, we obtained 20-50 single viral genomes from pre-therapy
plasma samples from 5 subjects who initiated therapy during
acute infection and 3 subjects who initiated therapy during chronic
infection. Pre-therapy plasma viral sequences were compared to
single proviral HIV-1 genomes derived from HIV-1-infected T-cells
(naı̈ve, memory, central- and effector-memory) from peripheral
blood (PB) and gut-associated lymphoid tissue (GALT) samples
collected after 4-12 years of suppressive therapy. Maximum likelihood
phylogenetic trees were constructed using the general time reversible
model incorporating rate variation among sites. Evolutionary diver-
gence was explored using root-to-tip analysis (Path-O-Gen).
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Results: The geometric mean infection frequency of memory
and naı̈ve CD4 T-cells in the PB was 13- and 24-fold higher
respectively in subjects treated during chronic compared to acute
infection. This was also true for effector memory CD4 T-cells from
the GALT (6-fold higher). Phylogenetic analysis revealed clear evidence
against any substantial evolution between the pre-therapy plasma-
derived HIV RNA sequences and on-therapy intracellular HIV DNA
sequences. Numerous intracellular HIV sequences identified after
long-term therapy contained replication-incompetent virus. One
patient had a predominant intracellular clone in both memory and
effector memory T-cells containing a 380bp deletion after 9 years of
therapy.
Conclusion: Early initiation of effective therapy results in substan-
tially lower reservoir size in blood and gut. The lack of HIV-1 genetic
evolution in the HIV-1 infected CD4 T-cell populations after years
of therapy argues against virus replication as a major cause of
persistence in these cell populations. The role of replication in other
tissues and cell types however remains to be defined.
A30 - Host cellular factors and latency
TUAA0103
Anti-APOBEC3G activity of HIV-1 Vif protein from elite
controllers is attenuated compared to those from untreated
chronic progressors or those from individuals with acute
infection
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T. Miura8
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Background: HIV-1-infected individuals who control viremia to below
the limit of detection without antiviral therapy have been termed
elite controllers (EC). Functional attenuation of some HIV-1 proteins
has been reported in EC. However, little is known about role of the
HIV-1 accessory protein Vif function in EC, which enhances HIV-1
infectivity through APOBEC3G degradation. In this study, the anti-
APOBEC3G function of Vif was compared between EC, chronic
progressors (CP) and individuals with acute infection (AI).
Methods: Forty-nine EC, 49 CP and 44 AI were studied. vif genes
were amplified by nested RT-PCR using concentrated plasma. To
compare anti-APOBEC3G activity of Vif proteins among those groups,
VSV-G-pseudotyped viruses were generated by co-transfecting 293T
cells with expression plasmids encoding patient-derived Vif,
APOBEC3G, VSV-G, together with a vif/env-deficient HIV-1 proviral
DNA clone carrying a luciferase reporter gene. VSV-G-pseudotyped
viruses were normalized for p24 antigen and used to infect 293T cells
and luciferase activity was measured at 48 h postinfection.
Results: Anti-APOBEC3G activity of Vif from EC was significantly
reduced compared to those from CP or AI (Figure 1). These results
remained significant after excluding individuals expressing protective
HLA alleles B*27 and/or B*57. No significant difference was observed
between CP and AI. Significant differences in amino acid usage in vif
genes were found at 7 residues between CP and EC, and at 13
residues between AI and EC. However, there were no common
polymorphisms (away from consensus B) that could explain reduced
anti-APOBEC3G activity of Vif derived from EC.
Conclusion: Anti-APOBEC3G activity of Vif proteins derived from EC
was reduced. This reduced activity was independent of presence or
absence of known protective HLA alleles. Common Vif mutations in
EC unlikely explain the observed reduction; rather it might be
attributable to unique mutations to each EC Vif protein.
TUAA0203
CBF-1 induces both establishment and maintenance of HIV
latency via recruiting PcG corepressor complex at LTR
M. Tyagi
George Mason University, Manassas, United States
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Background: Repressive epigenetic modifications have been shown
to induce and maintain HIV latency; however underlying molecular
mechanisms are not yet clear. We have previously demonstrated the
critical role of CBF-1 (Latency-C-promoter binding factor 1) in
establishing repressive chromatin structures at HIV LTR during
latency establishment. The knockdown of CBF-1 results in the
reactivation of latent proviruses and overexpression of CBF-1
facilitates latency establishment. Here we extend these studies to
show that multiple repressive epigenetic modifications that CBF-1
induces are the result of recruitment of Polycomb Group (PcG)
corepressor complex at HIV LTR by CBF-1.
Methods: Both transformed and primary T cells were infected with
lentiviral vectors expressing Tat in cis to study the underlying
molecular mechanisms regulating HIV latency and via running
various molecular assays, including Chromatin Immunoprecipitation
(ChIP) assays.
Results: In this study, we demonstrate that CBF-1 induces repressive
chromatin structures at HIV LTR by recruiting Polycomb Group (PcG)
corepressor complex at HIV LTR. The knockdown of endogenous CBF-
1 results in the dissociation of PcG complex components from HIV
LTR. Furthermore, knockdown of the individual components of PcG
complex leads to the reactivation of latent HIV proviruses demon-
strating the direct role of PcG complex in establishing HIV latency.
Overall our results demonstrate that the CBF-1 induced various
Figure 1. Comparison of anti-APOBEC3G activity of Vif From AI, CP
and EC patients.
Each dot represents mean RLU of each patient.
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epigenetic modifications are the result of recruitment of Polycomb
Group (PcG) corepressor complex at HIV LTR, which carry a variety of
epigenetic factors that repress HIV gene expression via generating
several layers of repressive epigenetic modifications.
Conclusion: We have established that analogous to the transformed
T cell lines in primary T cells CBF-1 induced repressive chromatin
structures play important role in establishing HIV latency. Addition-
ally by recruiting PcG corepressor complex at LTR, CBF-1 not only
facilitates HIV latency establishment also play critical role in
maintaining and stabilizing the latent proviruses.
THAA0103
Distribution of the HIV reservoir in patients spontaneously
controlling HIV infection after treatment interruption
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Background: Virological and Immunological Studies in CONtrollers
after Treatment Interruption (VISCONTI) are required to understand
the benefits of an early treatment at acute HIV-1 infection on the HIV
reservoir. We studied the distribution, magnitude and inducibility of
the HIV reservoir in VISCONTI patients.
Methods: The prospective VISCONTI study included twelve patients
controlling HIV for a median of 76[IQR:67.584.5] months after
interruption of a 3[IQR:1.75.9] years long HAART initiated within 10
weeks post-infection. Circulating resting CD25-CD69-HLADR- CD4T
cell subsets were sorted as naive (TN), central-memory (TCM),
transitional-memory (TTM) and effector-memory cells (TEM) for
further cell-associated HIV-DNA quantification by ultrasensitive real-
time-PCR, and viral inducibility by culture with anti-CD3/anti-CD28/
IL-2/IL-7. Reservoir distribution was compared to the one observed
in 8 untreated Elite-Controllers for whom 90% of HIV-RNA measures
was undetectable (below 200 copies) over 12[914] years.
Results: In the VISCONTI group, activated CD4T cells had
significantly higher HIV-DNA levels than resting ones (median
2.7[IQR:2.43.4] and 2[IQR:1.82.5] log copies/million cells,
p0.005). HIV-DNA was detected in all subsets from all patients
except for 8 out of 12 TN-sorted cells, which were 10 fold less
infected than all memory subsets (median TN:1.5[IQR:1.21.6],
TCM:2.5[IQR:1.82.9], TTM:2.6[IQR:2.22.8] and TEM:2.4[IQR:2
2.8] log copies/million cells, pB 0.007). TTM was the major subset
contributing to 56% of this reservoir. The same HIV reservoir
characteristics were observed in Elite-Controllers in term of magni-
tude and distribution, except that both TCM and TTM equally
contributed to the Elite-Controllers HIV reservoir. The VISCONTI HIV
reservoir was inducible after TCR-stimulation in all sorted memory
subsets from all patients, except in TN where no virus was recovered
in 6 out of 8 patients.
Conclusion: In VISCONTI patients, treatment initiated at primary
HIV-1 infection leads, after treatment interruption, to a low -but
inducible- durable HIV reservoir distributed mainly in short-lived
memory CD4T cells that mimicks the natural distribution observed
in Elite-Controllers.
MOPDA0105
Immune and inflammatory gene expression in the
periphery and CNS of cART-treated SIV-infected macaques
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Background: A major hurdle toward curing HIV is the establishment
of long-lived latent reservoirs such as the CNS. Using an SIV model of
HIV infection we examined the effect of combination antiretroviral
therapy (cART) on immune and inflammatory gene expression in the
periphery and CNS that leads to virus downregulation.
Methods: To examine the effect of cART on acute and long-term
systemic and CNS immunopathogenesis, groups of SIV-infected
macaques were untreated and euthanized at 21 postinoculation
(dpi) or end stage disease, or treated with cART starting at 4 or 12 dpi
and euthanized at 21 or 175 dpi, respectively. RNAs for immune and
inflammatory genes were quantified in the spleen and brain by non-
amplification Nanostring technology or by qRT-PCR. SIV replication
and viral DNA were also measured.
Results: cART initiation at 4 or 12 dpi did not prevent SIV seeding of
the brain; brain viral DNA levels were the same as in untreated
animals. cART treatment initiated at 4 dpi had little effect on
peripheral and CNS immune and inflammatory gene expression
profiles as compared to responses mounted in untreated macaques
after acute infection, as indicated by similar levels of IL17A, IL17F,
and CCL5 in the periphery and IL-6, IFNß, and TNFa in the CNS.
Conclusion: The CNS is a latent reservoir for SIV that is seeded early
after infection regardless of cART initiation at 4 or 12 dpi. The innate
and adaptive immune responses are nearly as effective as early cART
treatment at returning the host to peripheral and CNS immune
homeostasis by 21 dpi. However, at the same time those responses
likely promote the establishment of latent reservoirs by suppressing
viral replication, not eliminating the reservoir.
A31 - Host genetics of resistance and
susceptibility
MOPDA0101
Toll-like receptor (TLR) 9 variant is associated with mother-
to-child transmission (MTCT) of HIV-1 and TLR9 and TLR8
variants are associated with peak viral load in HIV-1-positive
infants
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United States. 4University of Washington, Global Health, Seattle,
United States. 5University of Washington, Pediatrics, Seattle,
United States. 6University of Nairobi, Nairobi, Kenya. 7University of
Washington, Seattle, United States. 8University of Washington,
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Background: Toll-like receptors (TLRs) are critical proteins of the
innate immune system. We evaluated association of single nucleo-
tide polymorphisms (SNPs) in 6 TLR and 2 TLR-associated genes with
infant HIV-1 acquisition and progression.
Methods: HIV-outcomes were assessed from birth to 1-year of age
among infants from a Kenyan perinatal cohort in which HIV-infected
women were enrolled during pregnancy and received short-course
zidovudine. Infants were genotyped for 6 candidate and 118
haplotype-tagging polymorphisms in TLRs 2, 3, 4, 7, 8, and 9,
MyD88 and TIRAP, and 144 ancestral informative markers. Cox
proportional hazards and linear regression were performed to assess
TLR polymorphism associations with HIV-1 acquisition, peak HIV-1
RNA levels, and infant mortality. Sex-stratified analyses of TLR7 and
TLR8 were conducted due to their X-chromosome location.
Results: Among 368 mother-infant pairs, 56 (15%) infants acquired
HIV-1 by month 1 and 17 (4.6%) between 1 and 12 months. Infants
with the TLR9 1635A (rs352140) variant were more likely to acquire
HIV by 1 month (HR1.49, 95% confidence interval [CI] 1.04
2.38, p0.028) and by month 12 (HR1.40, CI1.021.92,
p0.038) in additive models adjusted for maternal plasma HIV-1
viral load (VL) and genetic ancestry. Among 56 HIV-1 infected infants
infected atB1 month, peak VL was 6.8 log10 c/ml. The TLR9 1635A
allele was associated with a 0.40 log10 c/ml decrease in peak VL
(p0.002); female infants with the TLR8 1G (rs3764880) variant had
a 0.62 log10 c/ml increase in peak VL (p0.001). No variants were
significantly associated with mortality in infected infants.
Conclusion: This study is the first to evaluate the association
between TLR polymorphisms and HIV-related outcomes in a perinatal
African cohort and confirms TLR9 associations previously observed in
Caucasians. Defining the role of TLR polymorphisms in HIV-1
transmission and progression may inform future prevention strate-
gies that exploit the innate immune response.
MOPDA0102
Polymorphisms in TLR2 and TLR7 are associated with
plasma HIV-1 RNA set-point in an African heterosexual
cohort
R. Mackelprang1, A. Bigham2, C. Celum1, G. de Bruyn3, K. Beima1,
G. John-Stewart1, A. Ronald4, N. Mugo5, A. Rainer1, K. Buckingham1,
M. Bamshad1, J. Mullins1, J. McElrath1 and J. Lingappa1
1University of Washington, Seattle, United States. 2University of
Michigan, Ann Arbor, United States. 3University of the
Witwatersrand, Johannesburg, South Africa. 4University of Manitoba,
Winnipeg, Canada. 5University of Nairobi, Kenyatta National Hospital,
Nairobi, Kenya
Presenting author email: romelm@u.washington.edu
Background: The Toll-like receptor (TLR) genes mediate the innate
response to viral infections and may impact HIV-1 pathogenesis. We
evaluated TLR polymorphisms for association with plasma HIV-1 RNA
set-point in HIV-1 infected individuals from East and Southern Africa.
Methods: Analyses included prospective data and DNA from 500
Africans with heterosexually-acquired HIV-1 (125 incident, 375
prevalent). For incident HIV-1, set-point was defined as the median
plasma HIV-1 RNA level ]4 months after the estimated infection
date. For prevalent HIV-1, set-point was the average of ]2
consecutive plasma HIV-1 RNA measurements before ART initiation
or CD4 decline toB200 cells/mm3. Genotyping was performed for
124 single nucleotide polymorphisms (SNPs) from 6 TLR and 2 TLR-
associated signaling genes (TIRAP and MYD88) and 144 ancestral
informative markers. These included 8 candidate SNPs previously
associated with HIV-1, and 115 haplotype tagging SNPs (tagSNPs)
representing common variation across TLR genes. Associations were
determined using linear regression with adjustment for sex, age, and
population stratification, and Bonferroni correction.
Results: Among 492 HIV-1 infected individuals who passed
quality control, the median HIV-1 set-point was 4.6 (IQR: 3.85.0)
log10 copies/mL and did not differ between seroprevalent and
seroincident participants. TLR2-rs3804100 (minor allele frequency
[MAF]0.053), a candidate C-T synonymous SNP located in exon 1
was associated with an average 0.37 (95% confidence interval [CI]:
0.10, 0.65, p0.007) log10 copies/ml increased set-point. TLR7-
rs179012, a haplotype-tagging SNP located in intron 1 was associated
with a 0.31 (95% CI: 0.47, 0.14, Bonferroni-adjusted p0.032) log10
copies/ml decrease in HIV-1 set-point.
Conclusion: These are the first associations between TLR polymorph-
isms and plasma HIV-1 RNA level reported among African populations.
TLR2 rs3804100 has been previously linked with more rapid disease
progression in Caucasians. Our finding of TLR7 rs179012and improved
control of infection has not been previously reported. Further study of
these SNPs may improve understanding of HIV-1 pathogenesis.
MOPDA0103
Association of polymorphisms in the regulatory region of
cyclophilin A gene (PPIA) with disease progression and gene
expression levels
P. Madlala1,2, R. Singh1, L. Werner3, S. Sibeko3, P. An4, S.S.A. Karim3,
C.A. Winkler4 and T. Ndung’u1
1University of KwaZulu-Natal, Nelson R. Mandela School of Medicine,
HIV Pathogenesis Programme (HPP), Durban, South Africa.
2University of KwaZulu-Natal, Genetics, Pietermaritzburg, South
Africa. 3University of KwaZulu-Natal, Nelson R. Mandela School of
Medicine, Centre for the AIDS Programme of Research in South
Africa (CAPRISA), Durban, South Africa. 4National Cancer Institute-
Frederick, Basic Research Laboratory, Frederick, United States
Presenting author email: madlalap@ukzn.ac.za
Background: Human cyclophilin A (CypA) encoded by peptidyl prolyl
isomerase A gene (PPIA), is an important cellular co-factor for
efficient human immunodeficiency virus type 1 (HIV-1) infection. In
this study we investigated the effect of genetic variation in the
regulatory region of PPIA on HIV-1 disease progression and CypA
mRNA expression levels in HIV-1 South African cohorts.
Methods: A total of 603 black South African participants from
these cohorts were genotyped for single nucleotide polymorphism
(SNP) A1650G in the regulatory region of CypA using PCR-RFLP. 247
(195 HIV-1 seronegative participants [SNs] and 52 primary infected
participants [SPs]) participants were from the CAPRISA acute infec-
tion (AI) 002 cohort and 356 HIV-1 chronically infected participants
were from the Sinikithemba cohort. CypA mRNA expression was
quantified in 30 SNs and 28 SPs from the CAPRISA AI 002 cohort by
real-time RT-PCR. Lastly, we assessed the effect of SNPA1650G on viral
(NL4.3) replication in PBMCs isolated from HIV-1 negative individuals.
Results: The minor allele (G) of SNP A1650G (referred to as 1650G)
was significantly associated with higher viral load (pB0.01) and
lower CD4 T cell count (pB 0.01) during primary HIV-1 infection.
Interestingly, the1650G was associated with rapid CD4 T cell decline
during chronic infection (p0.01). The 1650G was also significantly
associated with higher CypA mRNA expression levels (pB0.01).
PBMCs isolated from participants harboring the 1650G supported
higher levels of NL4.3 replication ex vivo.
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Conclusion: Our results suggest that higher expression levels of CypA
mRNA enhance HIV-1 replication in a South African population. The
results demonstrate the clinical relevance of CypA and provide
additional in vivo validation of the CypA as a pertinent target for
therapeutic intervention. This study supports the development of
small molecule inhibitors against CypA and HIV-1 interaction.
WEPDA0101
HLA class I associations with rates of HIV-1 seroconversion
and disease progression in the Pumwani sex worker cohort
T. Peterson1, J. Kimani2,3, C. Wachihi2, T. Bielawny1, L. Mendoza4,
S. Thavaneswaran3, M. Narayansingh3, T. Kariri2, B. Liang3, E. Ngugi5,
F. Plummer3,4 and M. Luo1,3
1National Microbiology Laboratory, HIV and Human Genetics,
Winnipeg, Canada. 2University of Nairobi, Department of Medical
Microbiology, Nairobi, Kenya. 3University of Manitoba, Department
of Medical Microbiology, Winnipeg, Canada. 4National Microbiology
Laboratory, Winnipeg, Canada. 5Universiy of Nairobi, Department of
Community Health, Nairobi, Kenya
Presenting author email: trevp.87@gmail.com
Background: Class I Human Leukocyte Antigens (HLA) play an
important role in the adaptive immune response by presenting
antigens to CD8 T-cells. Previous studies have reported multiple
HLA associations with rates of disease progression in HIV infected
individuals, while few class I associations with resistance or
susceptibility to HIV-1 infection have been reported.
Methods: HLA-A, -B, and -C were typed for more than 1000 women
enrolled in the Pumwani sex worker cohort using a sequence-based
typing method. Kaplan-Meier analysis was used to identify alleles
influencing seroconversion and disease progression to AIDS (CD4
decline toB200/mm3).
Results: A*01 (P0.020), C*06:02 (P0.042) and C*07:01 (P
0.050) are independently associated with protection from seroconver-
sion. Women with any of these alleles are better protected from
seroconversion (P0.003, OR:1.988, 95% CI:1.2673.122) than those
without them. Conversely, A*23:01 (P0.004), B*07:02 (P0.003)
and B*42:01 (P0.025) are independently associated with rapid
seroconversion.Women with any of these alleles are twice as likely to
seroconvert (P0.002, OR:0.486, 95% CI:0.3040.775). The effect of
beneficial alleles in protection from seroconversion is more than three
fold when compared with those with susceptible alleles (P0.00004,
OR:3.636, 95% CI:1.9306.852). B*14(P0.003) and B*57:03(P
0.012) are independently associated with slower progression to AIDS,
while B*53:01(P0.035) is associatedwith rapid CD4 T-cell decline.
Women with B7 supertype rapidly progressed to AIDS and individuals
homozygous for this supertype fared even worse (P0.004).
Conclusion: Understanding why these HLA class I alleles are
associated with protection/susceptibility to HIV-1 acquisition and
disease progression could contribute to the development of effective
prophylactic and therapeutic vaccines for HIV-1.
A32 - Host restriction factors including
APOBEC, TRIM and others
WEPDA0206
TRIM22 repression of HIV-1 transcription is mediated by
interaction with SP1
A. Kajaste-Rudnitski1, S. Marelli1, G. Poli2, B. Berkhout3, A.T. Das3 and
E. Vicenzi1
1San Raffaele Scientific Institute, Milan, Italy. 2Vita-Salute San
Raffaele University, Milan, Italy. 3University of Amsterdam,
Department of Medical Microbiology, Amsterdam, Netherlands
Presenting author email: vicenzi.elisa@hsr.it
Background: We have recently shown that the IFN-inducible
Tripartite motif-containing protein 22 (TRIM22) suppresses basal
HIV-1 LTR-mediated transcription through a Tat-and NF-kB-indepen-
dent mechanism [Kajaste-Rudnitski et al., J Virol 2011, 85(10):5183
96]. In the absence of Tat/TAR RNA complex, HIV-1 transcription can
occur through the positive elongation factor (P-TEF) b function and
Sp1. We have here investigated whether TRIM22 interferes with Sp1-
mediated transcriptional activation of the HIV-1 LTR.
Methods: 293T cells, devoid of endogenous TRIM22, were trans-
fected with increasing amounts of a TRIM22-expressing plasmid
together with a fixed amount of an HIV-1 LTR reporter construct that
contains a TAR sequence unresponsive to Tat and two tet-O motifs
that bind to rtTA in the presence of doxycycline (Dox). Constructs
containing the deletion of one, two or three Sp1 sites were also
tested.
Results: TRIM22 efficiently inhibited Dox-induced WT HIV-1 LTR
transcription. Interestingly, this inhibitory effect was progressively
lost with the LTR reporters lacking one, two or all three Sp1 binding
sites, respectively. In line with these observations, addition of three
Sp1 sites into a reporter construct based on a CMV-derived promoter
element, normally insensitive to TRIM22, renders it susceptible to
TRIM22 transcriptional repression, indicating that TRIM22 could have
a broader regulatory role in Sp1-mediated gene expression. Although
TRIM22 does not alter overall Sp1 expression levels when transfected
into 293T cells, immunoprecipitation experiments performed on
293T cells transfected with a FLAG-tagged TRIM22 revealed that
TRIM22 directly interacts with Sp1.
Conclusion: These results suggest that TRIM22 may inhibit HIV-1
LTR-driven transcriptional initiation through interference with the
Sp1-mediated signaling and activation of early HIV-1 gene expres-
sion, rendering it an attractive candidate for novel therapeutic
approaches.
THPDA0204
Apobec3G levels are inversely associated with resting
CD4 T memory cell integrated provirus in vivo and
infectivity of reactivated HIV-1 ex vivo
M. De Pasquale1, Y. Kourteva2, T. Allos2 and R. D’Aquila2
1Vanderbilt University School of Medicine, Infectious Diseases,
Nashville, United States. 2Vanderbilt University School of Medicine,
Nashville, United States
Background: We hypothesized that APOBEC3G (A3G) was associated
with provirus burden in resting memory CD4 T cells, and infectivity
of HIV produced from them.
Methods: Cells from antiretroviral-naı̈ve, long-term non-progressor
(LTNP, n7) and HAART-suppressed (HS, n11) subjects were
negatively selected from PBMCs (Robo-Sep). Sorting (FACS Aria,
BD) separated activated cells (CD25, CD69, CD38 and HLA-
DR) from resting central memory (Tcm: CCR7, CD45RO),
resting effector memory (Tem: CCR7-, CD45RO, which includes
resting transitional memory) and resting naı̈ve (CCR7, CD45RO)
T cells. A3G was quantified by immunoblotting (Odyssey, Li-Cor).
Provirus was quantified by alu-PCR. Reactivated HIV was recovered
from cells treated ex vivo with anti-CD3,8 bispecific monoclonal
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antibody and IL2. Virus p24 levels in culture supernatants were
quantified by ELISA. Infectivity of virus produced from ex vivo
activated cells was assessed using TZM-bl indicator cells.
Results: Tcm and Tem from LTNP had less provirus in vivo than the
same cell type from HS subjects (p 0.01 for Tcm and 0.02 for Tem).
A3G protein levels were higher in Tcm and Tem from the LTNP, in
comparison to Tcm and Tem from the HS, subjects (p0.02 for Tcm
and p0.02 for Tem). Virions were recovered from ex vivo activated
Tcm from 5 of the HS subjects. Infectivities of normalized virion
amounts were inversely associated with the A3G levels in virions
produced from them (Spearman r-0.99, p0.01)
Conclusion: Resting central and effector memory CD4 T cells
from LTNP had less provirus and higher levels of A3G protein
than the same cell types from HS subjects. Infectivity of HIV
reactivated ex vivo from Tcm of HS subjects was inversely associated
with virion A3G levels. A3G appears able to restrict viral spread
from proviruses reactivated from resting memory CD4 T cells,
suggesting that improving this restriction may contribute to ’curing’
HIV.
A33 - Systems biology approaches to HIV
infection
WEPDA0201
Integration of global techniques to implicate post-
transcriptional regulation in HIV infection
J. Blackinton, M. Thompson, N. Mukherjee, S. Freel, G. Tomaras and
J. Keene
Duke University, Durham, United States
Presenting author email: jeff.blackinton@duke.edu
Background: The immediate and early dynamic cellular response to
an HIV virion entering the cell is not well understood, particularly at
the post-transcriptional level where known rapid immune responses
occur. Several RNA-binding proteins (RBPs) are known to be
important in infection, including HuR, which is known to bind to
and regulate the mRNA transcripts of several of the known early
entry co-factors such as PPIA, TRIM5, APOBEC3G and CUL5.
Methods: We have previously integrated three global methods to
measure post-transcriptional regulation in Jurkat T cell activation
and examine relationships between ribonucleoprotein (RNP) inter-
actions, transcription, RNA stability and translation. Dynamic changes
in association with HuR caused measurable effects on RNA stability
and translation of mRNAs. Transcripts that increased in association
with HuR during activation showed increased stability and translation
while those that decreased show decreased stability and translation.
Furthermore, these changed transcripts fell into relevant functional
groups, where cell cycle regulators were largely decreased in
association, stability and translation, and DNA/RNA regulators were
largely increased in association, stability and translation.
Results: To test the effect of post-transcriptional regulation in HIV
infection, we used the C8166 T cell line for a near complete and
synchronous infection and measured global changes in RNA stability
and rates of transcription using 4-thiouridine stability profiling at five
time points over the initial 24 hours of infection. Simultaneously, we
measured dynamic changes in mRNA association with HuR during
the same infection time points. Comparing the two datasets, we
observed several mRNA transcripts, including myc mRNA, a known
target of HuR, showing dynamic regulation at the level of stability
during the infection time course.
Conclusion: Elucidation of these events supports the involvement of
the post-transcriptional response early in HIV infection and suggests
that potentially modifying or amplifying the post-transcriptional
response may be able to reduce the efficiency of infection.
A34 - Mucosal transmission
MOAA0101
The effect of liquefaction on the ability of semen and
semen amyloid fibrils to enhance HIV infection
N. Roan1,2, J. Muller3, A. Gawanbacht3, O. Zirafi3, S. Chu1,
F. Kirchhoff3, J. Munch3 and W. Greene1,4
1The J. David Gladstone Institutes, Gladstone Institute of Virology
and Immunology, San Francisco, United States. 2University of
California at San Francisco, Department of Urology, San Francisco,
United States. 3Institute of Molecular Virology, Ulm University
Medical Center, Ulm, Germany. 4University of California at San
Francisco, Departments of Medicine, Microbiology and Immunology,
San Francisco, United States
Presenting author email: nroan@gladstone.ucsf.edu
Background: Semen, the most common vector for HIV transmission,
enhances HIV infection in vitro.We recently identified amyloid fibrils
comprised of fragments from semenogelins, the predominant
component of the semen coagulum. Semenogelin amyloids interact
with virions (Figure 1) and potently enhance HIV infection of
target cells. During semen liquefaction, semenogelins are fragmen-
ted and eventually completely degraded by PSA. We hypothesized
that if semenogelins are important for the viral enhancing activity
of semen, then the change in the levels of these proteins
during liquefaction should affect the ability of semen to enhance
infection.
Figure 1. Roan et al.
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Methods: Seminal fluid liquefied for different amounts of time were
assayed for viral enhancing activity and semenogelin levels in the
absence or presence of PSA inhibitors. We also tested the effect of
purified PSA on the activity of amyloids formed from chemically-
synthesized semenogelin peptides.
Results: The viral enhancing activity of semen decreases with
increasing liquefaction time in a manner that parallels the degrada-
tion of semenogelins. Semenogelin degradation and loss of viral
enhancing activity in semen are both prevented in the presence of a
PSA inhibitor. Finally, PSA specifically cleaves and inhibits the viral
enhancing activity of semenogelin fibrils.
Conclusion: Seminal fluid’s viral enhancing activity is retained for
several hours and then progressively decreases during prolonged
liquefaction. We found a correlation between activity and semeno-
gelin levels during liquefaction. These findings underscore the
importance of semenogelins for the viral enhancing activity of
semen. We also provide evidence that PSA directly regulates the
activity of semenogelin fibrils, suggesting that these amyloids are
regulated by liquefaction. As such, mechanisms to enhance the
natural liquefaction process may be a useful approach to limit the
ability of semen to enhance viral transmission.
MOAA0103
Impact of depot medroxyprogesterone (DMPA) on human
vaginal leukocytes and HIV-1 target cells
N. Chandra1, A. Thurman1, S. Anderson1, T. Cunningham2, C. Mauck1
and G. Doncel1
1CONRAD, Eastern Virginia Medical School, Norfolk, United States.
2Eastern Virginia Medical School, School of Public Health, Norfolk,
United States
Presenting author email: thurmaar@evms.edu
Background: The relationship between exogenous contraceptive
hormones and permissiveness of the female genital tract to human
immunodeficiency virus type 1 (HIV-1) remains the subject of intense
debate, due to a recent study showing a two-fold increase in the rate
of acquisition and transmission in serodiscordant couples using
depot medroxyprogesterone acetate (DMPA)[1]. In order to better
characterize the effect of DMPA on the vagina, we compared the
leukocyte populations and density of epithelial junction proteins in
vaginal tissue biopsies of women at baseline (during both the
follicular and luteal phases of the menstrual cycle) and 12 weeks
after receiving one DMPA injection.
Methods: Vaginal biopsies were obtained from 20 healthy women in
the follicular and luteal phases of the menstrual cycle, and
approximately 12 weeks after receiving a 150 milligram intramus-
cular injection of DMPA. Leukocyte populations, activation pheno-
type and epithelial thickness and tight junction and adherens
proteins were measured by immunohistochemistry and integrated
optical density. Statistical analyses were performed using Wilcoxon
signed rank tests.
Results: After DMPA administration, CD3, CD8, CD45, CD68, HLA-DR
and CCR5 bearing lymphocytes were all significantly (pB0.05)
increased in vaginal tissues, compared to the follicular and or luteal
phases. There were no significant differences in vaginal leukocyte
populations between the follicular and luteal phases of the control
cycle (p0.05). Epithelial thickness and tight junction and adherens
proteins were not statistically different between sampling times
(p0.05).
Conclusion: After exposure to DMPA, vaginal leukocyte populations
significantly increase in the vaginal mucosa. In absence of changes in
epithelial integrity, the increase in vaginal T cells, activation markers,
and HIV-1 receptors point to a possible immunological basis for the
observed effects of DMPA on HIV-1 acquisition and transmission in
women.
MOAA0105
HIV-1 transmission from semen to cervicovaginal tissue
ex vivo
A. Introini1, C. Vanpouille1, A. Lisco1, J.-C. Grivel1, A. Munawwar2,
S. Singh2 and L. Margolis1
1National Institute of Child Health and Human Development,
National Institutes of Health, Bethesda, United States. 2All India
Institute of Medical Sciences, New Delhi, India
Presenting author email: margolis@helix.nih.gov
Background: Semen is the main carrier of sexually transmitted
viruses, including HIV-1. However, semen of HIV-infected men is not
merely a passive transporter of HIV-1 but, because of its richness in
biologically-active compounds, including chemokines, may facilitate
HIV-1 transmission. To test this hypothesis and to study HIV-1
transmission under controlled conditions, we evaluated HIV-1 loads
and the cytokine milieu in semen and blood from infected men
as well as, the role of these cytokines in HIV transmission to
cervicovaginal tissue ex vivo.
Methods: We measured 21 cytokines/chemokines with a multiplex
bead assay and evaluated the loads of HIV-1 in seminal and blood
plasmas from 50 HIV-1-infected and 28 uninfected Indian men.
Results: We found that semen and blood are two separate
immunological compartments, in which concentrations of cytokines
and loads of coinfecting herpesviruses are profoundly different. Upon
HIV infection, the levels of blood and semen cytokines were
significantly altered, thus facilitating cytokine network compartmen-
talization. HIV-1 infection changes the seminal cytokine spectrum by
upregulating 16 of the 21 measured cytokines, while in blood 2
cytokines were downregulated and 7 were upregulated. One of the
most prominent cytokine in semen was IL-7, which was significantly
upregulated in semen of HIV-1-infected individuals. IL-7 in concen-
trations similar to that in semen of HIV-1-infected individuals
facilitates HIV-1 infection in cervicovaginal tissue ex vivo. This
facilitation is associated with a suppression of apoptosis of infected
CD4 T cells.
Conclusion: HIV-1 infection results in an aberrant production of
cytokines, changing the seminal cytokine network. The altered
seminal milieu is an important determinant of HIV-1 sexual
transmission: Cytokines altered by seminal infection facilitate HIV-1
transmission to cervicovaginal tissue ex vivo. Cervicovaginal tissue
infected ex vivo provides a platform to study the mechanisms of this
phenomenon and to develop new preventive strategies by targeting
the seminal microenvironment.
MOLBA03
HIV-1 female-to-male sexual transmission: evaluation of
circumcised and uncircumcised penile tissue
M. Dinh1, M. Anderson1, C. Gioia1, M. McRaven1, Z. Okocha1,
G. Cianci1, T. Hirbod2, G. Kigozi3, J. Prodger4, R. Kaul4, X. Kong5,
R. Gray5 and T. Hope1
1Northwestern University Feinberg School of Medicine, Cell and
Molecular Biology, Chicago, United States. 2Karolinska Institutet,
Stockholm, Sweden. 3Rakai Health Sciences Program, Entebbe,
Uganda. 4University of Toronto, Toronto, Canada. 5Johns Hopkins
Bloomberg School of Public Health, Baltimore, United States
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Background: Male circumcision has been shown to decrease rates of
HIV acquisition in African men. The STEP vaccine trial also demon-
strated that vaccinated, uncircumcised men were at increased risk
for HIV acquisition. We sought to identify the mode(s) by which HIV
infection may occur in uncircumcised men.
Methods: Foreskins were obtained from consenting male donors
receiving prophylactic male circumcision in Rakai, Uganda. Whole
penile specimens were obtained from tissue donation organiza-
tions (ScienceCare and NDRI). Using fluorescent immunohisto-
chemistry, foreskin keratin layers were labeled with filaggrin and
involucrin markers. Penile tissues were incubated with ex vivo
with photo-activatable GFP-linked-Vpr HIVBal for 4 hours, snap-
frozen, and cryosections stained for target cells and keratin. Images
were obtained with epifluorescent microscopy and analyzed for
keratin thickness, viral particles, and viral penetration into penile
epithelia.
Results: We found no significant differences between inner and
outer foreskin keratin layers from 19 foreskin samples obtained in
Uganda, indicating that reduced keratin thickness is not likely
to make the inner foreskin more susceptible to HIV. Preliminary
data from whole penile specimens (uncircumcised n7, circumcised
n7) shows no significant difference in number of visualized
virions per image captured, but more virions entering uncir-
cumcised as compared to circumcised glans tissue (uncir-
cumcised:circumcised2:1). Virions were found at distances from
the epithelial surface (mean9SD33.5922.3 mm) in the range
where CD4 cells are also localized (mean9SD53.6 932.3 mm),
in the absence of trauma to the epithelium. Finally, we visualize
virions interacting with the male urethral pseudo-stratified columnar
epithelia, though to a lesser degree than seen with stratified
squamous epithelia (n5, glans:urethra2:1).
Conclusion: These preliminary results suggest preferential routes by
which HIV-1 may enter the male genital tract in female-to-male HIV
sexual transmission.
A36 - Acute and early HIV infection
WEAA0105
The HIV-1 envelope protein gp120 mimics MAdCAM and
VCAM in binding to Integrin-a4b7
F. Nawaz1,2, C. Cicala1, D. Van Ryk1, D. Wei1, M. Pascuccio1,
S. Shrestha1, J. Knox1, C. Schwing1, J. Hiatt1, J. Chang1, K. Jelicic1,
A. Fauci1 and J. Arthos1
1NIAID, National Institutes of Health, Bethesda,
United States. 2New York University School of Medicine, New York,
United States
Presenting author email: nawazf@niaid.nih.gov
Background: Our laboratory previously reported that HIV binds
and signals through Integrin-a4b7, the gut homing receptor, on
the surface of CD4 T-cells. This interaction may be critical during
the earliest events of HIV transmission, when the virus rapidly
homes to the gut and a massive depletion of gut CD4 T cells
ensues. Understanding the precise manner by which the virus
engages a4b7 may therefore provide insights into the earliest
events in HIV infection and the design of novel therapeutics. Both
its natural ligands (MAdCAM and VCAM) and gp120 bind a4b7 in
a cation-dependent manner. In each case a divalent cation bound
to the integrin coordinates an aspartic acid (Asp) residue in the
ligand. We previously described a highly conserved Asp in the V2-
loop of gp120 that mimics the natural ligands of a4b7, and plays
a critical role in this interaction. However, MAdCAM and VCAM
utilize a second Asp residue and a second coordinating cation to
mediate recognition of both a4 and b7 chains in a complex way.
Our data suggests that gp120 interactions with a4b7 are similarly
complex.
Methods: To identify critical residues in HIV-gp120 that
mediate a4b7-reactivity we designed site-directed Asp mutants in
recombinant gp120s, and measured the binding of each mutant
to a4b7.
Results: By this approach, we identified two sites that mediate
gp120-a4b7 interactions. A single Asp mutant at either position
reduced reactivity with a4b7 by2-fold relative to the wildtype,
while the double Asp mutants diminished a4b7 binding to near-
undetectable levels.
Conclusion: This observation reveals the discontinuous nature
of the gp120-a47 epitope and suggests gp120 interactions with a47
closely mimic MAdCAM and VCAM. These results advance
upon our previous understanding of the molecular basis of a4b7-
gp120 interactions and lay the groundwork for further structural
studies.
A37 - Highly exposed seronegative
individuals (HESN)
MOAA0203
HIV-1 peptide-specific NK cell responses in HIV seropositive
and highly exposed seronegative men
R. Fecek, R. Mailliard and C. Rinaldo
University of Pittsburgh Graduate School of Public Health, Infectious
Diseases and Microbiology, Pittsburgh, United States
Presenting author email: rof19@pitt.edu
Background: Highly exposed seronegative (HESN) individuals have
had repeated exposures to HIV-1 yet remain virus and antibody
negative. We evaluated HIV-1 specific NK cell responses in men who
have sex with men (MSM) defined as HESN based on high-risk sexual
activities engaged in the early 1980’s.
Methods: Fresh, whole blood samples from HIV-1 seropositives
on ART (HIVpos), HIV-1 seronegatives (HIVneg), and HESN subjects in
the Multicenter AIDS Cohort Study were cultured with overlapping
15-mer peptide pools representing consensus sequences of
HIV-1 Gag, Env, and Reg (Tat, Rev, Vif, Vpu, Vpr), or peptide diluent
(Tiemessen, et al., JID 2010). The cultures were analyzed for
CD3-CD56 NK cell and CD3CD8 T cell responses by flow
cytometry.
Results: HIV-1 peptide-specific NK cell IFN-g and TNF-a responses
were present in 19/23 (83%) HIVpos, 6/13 (46%) HESN and 4/21
(19%) HIVneg (PB 0.001 and P0.07 compared to HIVpos and
HESN, respectively). The IFN-g response magnitudes ranged from 1%
to 20% of all NK cells: HIVpos5.691.1%, HESN1.590.7%,
and HIVneg0.4790.1% (PB 0.001 and P0.065 compared to
HIVpos and HESN, respectively). HIVpos NK cells predominately
responded to Env peptides, whereas HESN NK cells responded to
both Env and Reg peptides. While both HIVpos and HESN
demonstrated CD8 T-cell responses to Env and Reg, only HESN
had CD8 T-cell IFN-g reactivity to Reg in association with NK cell
responses.
Conclusion: We show for the first time that contemporaneous
blood samples from MSM defined as HESN exhibit relatively
robust, innate NK cell immunity, and less common CD8 T cell
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immunity, specific for HIV-1 proteins. These presumably long
lasting, NK cell responses to Env and Reg peptides could be due to
prior exposure to HIV-1, or to an inherited genetic resistance.
In-depth assessment of these virus-specific NK cell responses
could be important in designing effective HIV-1 therapeutics and
vaccines.
WEPDA0102
Highly-exposed HIV seronegative persons (HESN) had
higher levels of inflammatory and immune activation-
associated serum biomarkers than lower risk HIV
seroconverters (LRSC)
O. Martinez-Maza1,2, R. Detels2, L. Magpantay3, J. Phair4,
J.H. Bream5, C.R. Rinaldo6 and L.P. Jacobson7
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Background: Marked differences are seen in individuals’ suscept-
ibility to HIV infection. Inflammation and immune activation are
critical factors contributing to initial infection with HIV. The objec-
tive of this study was to define serum levels of cytokines and
biomarkers of inflammation in participants in the Multicenter
AIDS Cohort Study (MACS) who were at high risk for acquiring HIV
infection but remained HIV seronegative (HESN), and in those at
lower risk who did (LRSC), or did not (LRSN), subsequently undergo
HIV seroconversion.
Methods: Serum levels of cytokines, and biomarkers for inflammation
were quantified using Luminex multiplexed assays, in 188 HESN, 125
LRSC, and 197 LRSN. LRSC were tested at a study visit preceding HIV
seroconversion. HESN were defined as persistently seronegative
participants who were multiply-exposed (45 anal sexual partners
in the 2.5 years prior to MACS visit 2). The LRSC and LRSN groups
hadB20 anal partners during this same period. CCR5D32
homozygotes were excluded from the HESN group. Age-adjusted
left-censored generalized gamma regression models were used to
compare levels and logistic regression models for detectability across
groups.
Results: HESN men demonstrated significantly lower age-adjusted
serum levels of APO-A1 (P0.036) and higher levels of sTNFR2
(P0.022) than LRSC. Additionally, HESN men demonstrated
significantly higher serum levels of sTNFR2 (P0.014), sCD27
(P0.035), sCD14 (P0.014), and IL-8 (PB 0.004), and lower
serum levels of CXCL13 (P0.034) and IFNg (P0.22), than LRSN.
The likelihood of having detectable IL-2, IL-4, and IL-12 was higher in
LRSN vs HESN, but detection of these biomarkers was similar
between LRSC and HESN men.
Conclusion: HESN men displayed lower age-adjusted serum levels of
an anti-inflammatory molecule, APO-A1, and higher levels of a
molecule associated with enhanced TNF responses (sTNF-R2) than
did LRSC. These results are consistent with enhanced immune
responsiveness and inflammation being associated with resistance
to persistent infection with HIV.
A38 - Mother-to-child transmission
WEAA0203
Target cell restriction may limit mother-to-child
transmission of SIV in sooty mangabeys
A. Chahroudi1,2, D. Carnathan2, P. Carnathan2 and G. Silvestri2
1Emory University School of Medicine, Pediatrics, Atlanta,
United States. 2Yerkes National Primate Research Center, Atlanta,
United States
Presenting author email: achahro@emory.edu
Background: Mother-to-infant transmission (MTIT) of HIV results in
400,000 infected children each year, with a transmission rate of
3540%. In contrast, nonhuman primate species that are naturally
infected with SIV in the wild (‘‘natural hosts’’, including sooty
mangabeys, SMs) rarely transmit SIV from mothers to infants. The
mechanisms underlying this protection are unknown. In this study
we tested the hypothesis that limited target cell availability protects
SMs from MTIT.
Methods: The availability of target cells (CD4CCR5 and
CD4Ki67 T-cells) for SIV infection in seven uninfected SM infants
was measured by flow cytometry among naı̈ve and memory T-cell
subsets obtained from tissues (lymph nodes, spleen, tonsil, and
multiple sites along the gastrointestinal tract) at necropsy.
Results: We found that, in infant SMs, the median percentage of
CD4Ki67 T-cells ranged from 3.2%-10.3% depending on the anat-
omic site analyzed, with lower values found in CD95-CD28 naı̈ve
CD4 T-cells. In contrast, the CD95CD28CCR7 central memory
and CD95CD28CCR7- transitional memory CD4 T-cells dis-
played higher median levels of Ki67 (10.4%-49.3%). The percentage of
Ki67CD95CD28-CCR7- effector memory CD4 T-cells tended to
be between that of the naı̈ve cells and other memory subsets. Despite
this increased level of proliferation (compared to adult SMs), CCR5T-
cells comprisedB10% (and, in most cases,B5%) of the CD4
lymphocyte population at all sites and within all T cell subsets, thus
revealing restricted expression of the SIV coreceptor in infant SMs.
Conclusion: We have shown that MTIT is substantially less frequent
in SIV-infected SMs than in HIV-infected humans. Here we demon-
strate that while robust T-cell proliferation is present in infant SMs,
SIV target cells (CD4CCR5 T-cells) are extremely limited in
multiple tissues. This finding reveals an additional, previously
unrecognized feature of the evolutionary adaptation to reduce the
risk of MTIT in SIV-infected SMs.
A39 - Preclinical HIV drug development
TUAA0301
Pre-clinical evaluation of HIV replication inhibitors that
target the HIV-integrase-LEDGF/p75 interaction
F. Christ1, C. Pickford2, J. Demeulemeester1, S. Shaw2,
B.A. Desimmie1, C. Smith-Burchnell2, S. Butler2, M. Westby2 and
Z. Debyser1
1KULeuven, Laboratory for Molecular Virology and Gene Therapy,
Leuven, Belgium. 2Pfizer Inc, Sandwich, United Kingdom
Presenting author email: frauke.christ@med.kuleuven.be
Background: Current HIV-1 integrase inhibitors target the catalytic
activity, which is vital for sustained viral infection. Integrase mediates
the critical step of proviral DNA integration. Efficient integration also
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requires a crucial cellular co-factor of HIV-1 integrase, LEDGF/p75,
that tethers the viral DNA to the host chromatin. LEDGINs, small
molecules designed to bind to the LEDGF/p75 interaction site on IN
and to disrupt the interaction, have recently been shown to act as
potent inhibitors of HIV replication in cell culture.
Methods: We have now analyzed the detailed mode of action of
LEDGINs, dissecting the allosteric nature of inhibition in vitro and
analyzing phenotypically their activity in cell culture. Mechanistic
studies and combination experiments shed light on potential synergy
of LEDGINswith known integration inhibitors. Analysis of the inhibition
of a broad spectrum of HIV strains allows predictions on combinations
with other drugs such as entry, RT and protease inhibitors.
Results: Biochemical evaluation of LEDGINs demonstrates in addition
to a potent inhibition of the integrase-LEDGF/p75 interaction, a block
of the catalytic integrase activities. This allosteric inhibition is
promoted by the stabilization of the dimer-interface of IN upon
LEDGIN binding most likely by affecting interaction with viral DNA.
These properties of LEDGINs result in potent inhibition of HIV
replication in both MT2 and PBMC cells. Moreover, LEDGINs are
active across a broad range of HIV clades. LEDGINs retained full
activity against a panel of viruses containing mutations that confer
resistance to integrase strand transfer inhibitors. Combining LEDGINs
with strand transfer inhibitors demonstrates a synergistic effect of
these classes of integration inhibitors.
Conclusion: The biochemical data together with the lack of cross resis-
tance and the observed synergistic effects of LEDGINs in combination
with strand transfer inhibitors support the potential for combined use
of LEDGINs with strand transfer inhibitors in HIV therapy.
A40 - Preclinical development of
microbicides
WEPDC0103
Development of a new intravaginal ring technology for the
extended delivery of the microbicide tenofovir with and
without the contraceptive levonorgestrel
T. Johnson1, M. Clark2, J. Clark1, N. Shelke1, G. Doncel3, D. Friend2
and P. Kiser4
1University of Utah, Bioengineering, Salt Lake City, United States.
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Obstetrics & Gynecology, Norfolk, United States. 4University of Utah,
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Background: Tenofovir (TFV) is the only microbicide antiretroviral that
has shown clinical effectiveness when dosed pericoitally in a vaginal
gel. There remains a need to improve TFV delivery by providing long-
lasting, coitally-independent, effective drug levels. Intravaginal rings
(IVRs) offer this capability; however TFV is hydrophilic and demon-
strates inadequate delivery from conventional IVR technologies. Our
objective was to develop a novel IVR technology capable of releasing
]10mg/d TFV for ]90 days, alone or co-deliveredwith 10 or 20 mg/d
of the contraceptive levonorgestrel (LNG).
Methods: IVRs were designed using single (TFV-only) or dual (TFV-
LNG) reservoir-type polyurethane (PU) segments. TFV segments
comprised water-swellable PU tubing filled with a high density TFV
paste. LNG segments comprising a LNG-loaded non-swellable PU
core with a rate controlling membrane were cut to 1 and 2 cm
lengths to obtain target release rates of 10 and 20 mg/d, respectively.
In vitro release testing (IVRT) and 3-month pharmacokinetic (PK)
studies in rabbits and sheep evaluated device performance.
Results: IVRT revealed time-independent and tunable TFV and LNG
release rates which were optimized to achieve our target 10 mg/d
TFV and 10 or 20 mg/d LNG. In sheep, TFV and LNG release rates were
estimated at 1217 mg/d and 1431 mg/d, respectively. TFV
vaginal tissue and fluid levels were 104 and 106 ng/g, respectively,
similar to levels reported after clinical dosing of TFV 1% gel. In
rabbits, LNG PK demonstrated 2-fold differences in plasma and
cervical tissue concentrations between the two dose groups, as
predicted by in vitro release.
Conclusion: We developed a unique IVR technology that met our
target product profile delivering a high flux of a hydrophilic
antiretroviral (TFV) alone or with a low flux of a hydrophobic drug
(LNG) in a controlled, time-independent manner. PK results are
highly encouraging and warrant a Phase I clinical study. [Picture of
prototype TFV and TFV/LNG IVRs]
A42 - Nucleic acid-based HIV and SIV
therapies
TUAA0302
Towards HIV eradication: excision of HIV-1 proviral DNA by
Tre-recombinase in HIV-positive humanized mice
Figure 1. Picture of prototype TFV and TFV/LNG IVRs.
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Background: HIV-1 integrates into the host chromosome and persists
as a provirus flanked by long terminal repeats (LTR).To date, treatment
regimens primarily target the virus enzymes or virus entry, but not the
integrated provirus. Therefore, HAART requires lifelong treatment
which is frequently accompanied by the occurrence of substantial side
effects and/or the development of drug-resistant viruses. Previously,
we engineered a LTR-specific recombinase (Tre-recombinase) that
effectively excises integrated HIV-1 proviral DNA from infected human
cell cultures, suggesting that customized enzymes might someday
help to eradicate HIV-1 from the body. Therefore, we here analyzed
the potential of Tre-recombinase to reverse HIV-1 infection in vivo.
Methods: We constructed an advanced lentiviral self-inactivating
(SIN) vector that expresses Tre-recombinase conditionally in HIV-
infected cells. We monitored Tre functionality and potential Tre-
related cytopathic effects over time in tissue cultures. Moreover, the
effect of Tre activity on HIV-1 infection was investigated in
humanized mice.
Results: It is shown that Tre-recombinase is efficiently delivered into
cells and accurately excises HIV-1 proviral DNA from chromosomal
integration sites. Apparently, prolonged overexpression of Tre-recom-
binase does not induce undesired cytopathic effects in the transduced
cells. Finally, we demonstrate pronounced antiviral activity of Tre-
recombinase in HIV-1 infected Rag2/?c/ mice, which were
either engrafted with Tre-transduced human CD4 Tcells or with Tre-
transduced human CD34 hematopoietic stem cells (HSC).
Conclusion: The presented data suggest that Tre-recombinase may
be a valuable component of future antiretroviral therapies of the
post HAART era that aim at virus eradication, thereby providing a
cure for AIDS.
TUAA0303
In vivo suppression of HIV by antigen specific T cells derived
from engineered hematopoietic stem cells
S. Kitchen, B. Levin, G. Bristol, V. Rezek, S. Kim, C. Aguilera-Sandoval,
A. Balamurugan, O. Yang and J. Zack
David Geffen School of Medicine at UCLA, UCLA AIDS Institute,
Los Angeles, United States
Presenting author email: skitchen@ucla.edu
Background: In HIV infection, the HIV-specific cytotoxic T lymphocyte
(CTL) response is a critical component in controlling viral replication
that ultimately fails in its ability to eradicate the virus from the body.
Our primary aim is the development of a way to enhance the HIV-
specific CTL response to allow long-term viral suppression or viral
clearance.
Methods: In our approach, we sought to genetically manipulate
human hematopoietic stem cells (HSCs) such that they differentiate
into mature CTLs that will kill HIV infected cells. To perform this, we
utilized molecularly cloned HIV-specific T cell receptors (TCRs) derived
from CD8 T cells. These TCRs were used to genetically transduce
HSCs that were introduced into a humanized mouse and were allowed
to differentiate into mature human CD8 CTLs. Mice expressing the
transgenic HIV-specific TCR and, separately, control mice were then
infected with HIV-1 and functional cellular responses, viral suppres-
sion, and viral and T cell dynamics were assessed.
Results: We found that genetic modification of human HSCs with a
cloned TCR allows proper differentiation of the cells to occur in vivo
and these cells migrate to multiple anatomic sites, mimicking what is
seen in humans. We observed that the genetically modified HIV-
specific CTLs form a functional antiviral response in vivo that results
in the significant suppression of HIV replication in multiple organs. In
addition, we found significant correlations between the levels of
reconstitution with cells bearing the HIV-specific TCR, antigen-driven
T cell expansion, and the control of viral replication.
Conclusion: We have developed a system to closely characterize the
engineering of antiviral immunity and HIV-specific CTL responses.
Our results strongly suggest that stem cell based gene therapy may
be a feasible approach in the treatment of chronic viral infections
and provide a foundation towards the development of this type of
strategy.
THPDA0202
Hematopoietic stem cell gene therapy targeting HIV-1 based
on lentiviral CCR5D32 and multiple microRNAs
L.-J. Chang1, G. Alkhatib2, L.-M. Huang3, Y. Chen1 and Y. Yeh1
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Background: Treatment of HIV infection by antiretroviral therapy is
effective but costly and often associated with numerous side effects.
The key to a permanent treatment to chronic HIV infections is to
elicit potent host resistance to viral infection and to restore immune
functions. The prolonged incubation period of HIV-1 provides a good
opportunity for applying non-conventional interventions such as
gene therapy. For HIV gene therapy to be effective, the combination
of an efficient gene transfer vector and a powerful anti-HIV strategy
is necessary.
Methods: HIV resistance will be established in patients? hemato-
poietic stem cells (HSCs) by lentivector (LV) transduction of (i) a
microRNA to block endogenous CCR5 expression, (ii) a sequence-
modified CCR5D32 gene to interfere with the function of native
CCR5 and CXCR4 and (iii) effective multiple anti-HIV shRNAs to target
viral RNAs.
Results: We generated LVs encoding the native and a codon-
optimized CCR5D32 gene. Ectopic expression of CCR5D32 in HOS-
R5 and Magi-R5 cells established protection against R5-HIV-1
infection. Unexpectedly, we observed severe cytotoxicity in HOS-R5
cells and primary CD4 T cells when CCR5D32 was expressed. In a
second approach, we generated a LV expressing an H1-promoter
driven CCR5 miRNA and demonstrated marked protection against
R5-HIV-1 infection. In a third approach, we generated a novel LV
expressing three miRNA intronic cassettes (miR155-19a-30a) target-
ing HIV-1 pol, int and vpu, respectively, and demonstrated marked
protection against HIV-1 infection. LV transduction of adult CD34
HSCs had no adverse effect on hemopoiesis for dendritic cell
development but T cell development appeared to be impaired based
on an in vitro assay.
Conclusion: We conclude that ectopic expression of CCR5D32 in
adult CD34 HSCs using a constitutive expression promoter is
cytotoxic because the CCR5D32 transgene can activate uncontrol-
lable intracellular T cell signaling. However, miRNAs targeting
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endogenous CCR5 and multiple HIV sequences is highly effective
against HIV infection without cytotoxicity.
A43 - B cell-based vaccines
MOLBA05
Stabilized exposure of conserved epitopes by structure
guided insertion of disulfide bonds in HIV envelope
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Background: The transition from native to receptor-bound and
eventually to the fusion-competent conformation of HIV-1 envelope
glycoprotein (Env) Env requires a tightly choreographed interaction
among highly conserved structures within the viral envelope
glycoprotein. Recent structural information has revealed that these
conformational transitions are regulated by three conserved but
highly mobile layers stacked between the receptor-binding domain
(gp120) and the fusion arm (gp41) of Env. We hypothesized that
limiting the mobility of these layers by artificially insertion of
covalent bonds will capture Env in a conformation where conserved
sites are stably exposed.
Methods: We scanned residues that lie at the interface of gp120
layers (layers 1, 2 and 3) and identified targets that are predicted to
form disulfide bonds if substituted with paired cysteines. We
substituted a pair of residues between layers 1 and 2 with cysteine
& expressed and purified the disulfide-stabilized gp120 (and gp140)
antigens and analyzed them using Surface Plasmon Resonance (SPR)
assay. Following in vitro analysis, we immunized rabbits with both
the wild-type and disulfide-stabilized gp120 (and gp140) antigens,
adjuvanted with CarbopolMF59, and evaluated serum antibodies
for binding, neutralization and epitope-specificity.
Results: A single disulfide bond inserted between the highly
conserved layers 1 and 2 led to enhanced stability of the receptor
bound conformation of gp120. This was revealed by lower dissocia-
tion constant (Kd) of the mutant gp120 binding to 17b antibody,
which recognized a conserved CD4 induced (CD4i)-epitope on gp120.
Upon immunization in rabbits, the disulfide-stabilized gp120 (and
gp140) antigens, in comparison to wild-type antigens, elicited higher
level of antibodies directed to CD4-binding site and CD4i-site.
Conclusion: We demonstrate that structure guided stabilization of
inter-layer interactions within Env can be used to improve and
stabilize the exposure of conserved epitopes on the antigen and elicit
improved antibody response, with the aid of a potent adjuvant, upon
immunization.
TUPDA0103
Novel DNA vaccine candidates that mimic the
neutralization-competent structure of the MPER of
HIV-1 gp41
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Background: The limited success of vaccines targeting the MPER of
HIV-1 gp41, we hypothesize, may in part reflect the difficulty of
mimicking its neutralization-competent structure (NCS). We have
developed DNA-vaccine candidates meant to emulate the NCS of the
MPER, and report on their ability to elicit MPER-specific, neutralizing
(Nt) antibodies (Abs).
Methods: DNA vaccines encoding various gp41 ectodomain frag-
ments, and the transmembrane region (TM) of either the platelet-
derived growth factor receptor (PGDFR), or that of gp41 were
engineered, transiently expressed in COS-7 cells, and tested for
antigenicity. Rabbits were immunized with plasmid DNA of select
candidates; sera were collected and tested for MPER reactivity.
Results:Work with the protein products of these vaccines has shown
they mimic the NCS of the MPER by several criteria, including the
ability to be bound tightly by well-characterized Nt MAbs, but weakly
by their non-neutralizing mutant-MAb counterparts. Immunizations
with plasmids expressing the MPER tethered to the PDGFR-TM
elicited MPER-specific Abs that targeted the epitope of the 2F5 NtAb.
Immunization with DNA vaccines encoding the MPER and gp41 TM,
elicited low-titre Abs that cross-reacted weakly with the MPER, and
strongly with regions outside the MPER. Both sets of immunizations
failed to produce Abs that cross-reacted with the 4E10 epitope, or
neutralized pseudoviruses bearing HIV-1 Env. We found that the
presence of the PGDFR-TM significantly reduced MPER-binding to
4E10 MAb, but not by 2F5. Putative models suggest that in the
PDGFR-TM fusions, the 4E10 epitope faces into the lipid bilayer,
thereby altering its exposure.
Conclusion: Our work reveals key structural features involved in
promoting the NCS of theMPER.While the gp41 TM is vital in properly
exposing neutralizing epitopes on the MPER, it was also found to
elicit Abs against sites outside the MPER. Current work is focused on
engineering the gp41 TM to optimally expose MPER epitopes.
A44 - T cell-based vaccines
WEAA0102
A novel HIV vaccine approach: targeting the protease
cleavage sites of HIV-1
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Background: The classical vaccine approach for combating other
viruses has failed so far in dealing with HIV-1, a virus infecting a key
component of immune system and with greater diversity and rapid
mutation. New approaches are needed to develop a preventative
vaccine.
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The protease of HIV-1 is a small 99-amino acid aspartic enzyme
mediating the cleavage of Gag, Gag-Pol and Nef precursor poly-
proteins. The process is highly specific, temporally regulated and
essential for the production of infectious virions. A total of 12
proteolytic reactions are required to generate a viable virion.
Therefore, a vaccine targeting the 12 protease cleavage sites(PCS)
could be effective. The PCS of HIV-1 are highly conserved, direct
immune responses against these sites would yield several advan-
tages. First, the immune response could destroy the virus before its
establishment in the host. Second, it could force the virus to
accumulate mutations eliminating the normal function of the HIV
protease. Third, restricting the immune responses to these sites can
avoid distracting immune responses that often generate unwanted
inflammatory responses, induce excess immune activation, and
attract more targets for HIV-1 infection, establishment and spread.
Methods: We conducted a pilot study to investigate the feasibility
and effectiveness of this approach. The recombinant VSV-peptides
were used to immunize cynomolgus macaques and nanopackaged
peptides were used to boost the immune response to the
12 PCS of SIVmac239. The controls and immunized macaques were
repeatedly challenged intrarectally with an increased dosage of
SIVmac239.
Results: Antibody and T cell responses to the 12 PCS can protect
macaques against higher dosage of SIVmac239 challenge (p0.0005,
R0.8005) and the vaccine group maintains significantly higher
CD4 counts (p0.0002) than the controls weeks after being
infected. Population coverage analysis showed that this approach
can be applied to 95% populations in the world.
Conclusion: Targeting 12 PCS of HIV-1 is a viable approach.
A45 - Novel vectors and strategies
WEAA0101
Characterization of early gene expression profile in the
blood of macaques immunized a Thai trail-like vaccine
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Background: A strategy combining Canarypox based vaccine, ALVAC-
HIV with gp120 protein has resulted in limited but significant
protection from HIV infection in The RV144 vaccine efficacy trial.
We have previously tested a similar strategy in the non-human
primate model of HIV infection obtaining a similar efficacy to what
observed in humans.
Methods: To study the contribution of innate immune responses
as correlate of protection, we have performed microarray analysis
in the blood collected from 6 macaques at 16, 24 48 and 72 hours
after the first two immunizations with ALVAC (V1 and V2 respec-
tively) and the 3rd immunization with ALVAC/gp120 protein (V3).
Results: Our results show that 1) 24h after the 1st immunization with
ALVAC-SIV (V1) genes with antiviral activity were up regulated (MX1,
HERC-5, CD79b), but interestingly inflammatory genes where down
regulated (IL1, IL18RAP, IFNR1), suggesting a reciprocal regulation of
genes for IFN type I and II; 2) similar patterns of gene expression
where observed earlier, at 16h from V2, suggesting the presence
of "memory -innate" anti viral responses; 3) the 3rd boost with
ALVAC, given simultaneously to the gp120 protein adjuvanted in
Alum (V3), resulted in significant changes in the gene expression
profile when compared to the first two vaccinations. At 24h from this
immunization there were a far less number of IFN-related genes that
were significantly up regulated (V33) when compared to the first
and second immunization (V1 17; V227), and the IFN-responses
still up regulated were associated with NK cells, B cell- (CD79B) and
T cell- (PKC, CD28 TCR) responses.
Conclusion: These results suggest that each component of vaccina-
tion could have contributed to the protection from infection
underscored the ALVA/gp120 strategy. Understanding how to induce
different types of immune responses that are protective for
HIV may be relevant for the generation of more effective vaccine
strategies.
A53 - Mycobacteria and tuberculosis
THPDA0101
Peripheral blood monocytes contribute to the immune
reconstitution inflammatory syndrome (IRIS): is the
complement system emerging to the spotlights?
H. Tran Thi Thanh1,2, R. Van den Bergh1,2, L. Kestens3, M. Massinga-
Loembe3, R. Colebunders3, P. De Baetselier1,2, G. Raes1,2 and TB-IRIS
Study Group
1Vrije Universiteit Brussel, Cellular and Molecular Immunology Unit,
Brussels, Belgium. 2Myeloid Cell Immunology Laboratory, VIB,
Brussels, Belgium. 3Institute of Tropical Medicine, Antwerpen,
Belgium
Presenting author email: thitran@vub.ac.be
Background: One of the most frequent complications associated
with antiretroviral therapy (ART) in HIV-tuberculosis (TB) co-infected
patients is the Immune Reconstitution Inflammatory Syndrome
(IRIS). While monocytes/macrophages play a major role in both
HIV- and TB-infection individually, the putative contribution of
monocytes to the development of TB-IRIS remains uncharacterized.
We therefore applied a parallel approach of genome-wide microarray
analysis and focused gene expression profiling in monocytes from
Ugandan HIV-TB co-infected patients before and shortly after ART
initiation, to investigate the possible functional contribution of
monocytes to the development of IRIS.
Methods: Monocyte gene expression of TB-IRIS patients and non-TB-
IRIS patients was analyzed by Affymetrix GeneChip
†
Human Gene
1.0 ST Arrays and was confirmed using the nCounter system; datasets
were analyzed for overrepresented pathways using Ingenuity Path-
way Analysis. Expression levels of and enzymatic activities of proteins
of interest were characterized in the isolated monocyte fractions and
in the plasma of IRIS patients.
Results: Pathway analysis indicated that the complement system was
significantly modulated in monocytes of TB-IRIS patients, both before
initiation of therapy (baseline) and after two weeks of therapy. At
baseline, expression of both C1q and C1-inhibitor was higher in TB-
IRIS patients. After two weeks, the C1q mRNA levels in the majority
of TB-IRIS patients increased, whereas C1-inhibitor mRNA levels
decreased pronouncedly. Additionally, the inhibitory activity of C1-
inhibitor was significantly higher in TB-IRIS patients compared with
non-TB-IRIS patients at baseline but reduced to the level of C1-
inhibitor activity in non-TB-IRIS patients at week 2.
Conclusion: For the first time, we provide evidence that monocytes
at least partially contribute to the development of TB-IRIS, probably
through the complement system response. An intriguing possibility
is that the relative balance between C1q and C1-inhibitor may
be affecting the inflammatory function of C1q in the complement
cascade.
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A55 - Interactions with other pathogens
THPDA0102
Cytokine storm in leishmania/HIV-1 co-infected patients can
be caused by LPS and leishmania infection
J. Santos-Oliveira1, C. Giacoia-Gripp1, E. Regis1, P. Alexandrino-
Oliveira2, V. Amato3, J.A. Lindoso3, H. Goto3, J. Guerra4, M. Mattos1,
M. Oliveira-Neto1, B. Grinzstejn1, M. Morgado1 and A. Da-Cruz1
1Oswaldo Cruz Foundation/ FIOCRUZ, Rio de Janeiro, Brazil. 2Federal
University of Mato Grosso do Sul, Rio de Janeiro, Brazil. 3University
of Sao Paulo (USP), Sao Paulo, Brazil. 4Tropical Medicine Foundation,
Manaus, Brazil
Presenting author email: joanna_reis@yahoo.com.br
Background: We have shown that leishmaniasis contributes to
heightened T-cell activation in HIV-1/Visceral leishmaniasis (AVL)
patients. Now we investigate whether lipopolysaccharide (LPS) has a
crucial role in the pathogenesis of this co-infection.
Methods: 10 healthy volunteers, 17 AVL/HIV-1 and 16 HIV-1/AIDS
patients were recruited. CD4T counts and CD8T cells expressing
CD38 were analyzed by flow cytometry. LPS and sCD14 levels were
measured by enzymatic assays. Plasmatic pro-inflammatory cyto-
kines (IL-1/IL-6/IL-8/IL-17/IFN-g/TNF-a) were assessed by multiplex
analysis. The macrophage migration inhibition factor (MIF) and
intestinal fatty acid binding protein (IFABP) were quantified by
ELISA. Mann-Whitney and Spearman correlation test were employed
for statistical analysis. Multivariate linear regression was used to
determine influence of intervenient factors over T-cell activation.
Results: AVL/HIV-1 patients in leishmaniasis remission presented
equal CD4T counts or T-cell activation levels in comparison to
patients in the active phase of leishmaniaisis. Higher levels of CD8/
CD38 were seen independently of leishmaniasis clinical phase
when compared to HIV/AIDS cases (pB 0.05). Viral load levels had
no influence in CD8/CD38 levels. Co-infected and HIV patients
presented similar LPS and IFABP levels, but higher than healthy
donors (pB 0.001). Pro-inflammatory cytokines levels, but not MIF
were significantly augmented in co-infected cases. LPS levels
were positively correlated with MIF (r0.40;pB 0.05). We found
positive correlation between LPS levels and CD38 on CD8 T
lymphocytes(pB0.001), independently of CD4 T counts, HIV
viremia, sCD14, MIF and IFAB levels. Leishmania infection was also
positively correlated with activation levels(pB 0.001). We also
observed that LPS and Leishmania infection were positively corre-
lated with IL-6(pB 0.05) and IL-8(pB 0.01) levels.
Conclusion: Leishmania/HIV-1 patients had an exacerbated pro-
inflammatory cytokine response. In addition, LPS contributes to
higher T-cell activation. In conclusion, Leishmania infection along
with LPS levels may contribute to cytokine storm, which in turn may
increase T-cell activation, worsening the condition of patients
harboring both pathogens.
THPDA0104
HIV-facilitated paracellular penetration of HPV into mucosal
epithelium
S. Tugizov1, R. Herrera1, P. Veluppillai2, D. Greenspan2 and J. Palefsky1
1University of California at San Francisco, Medicine, San Francisco,
United States. 2University of California at San Francisco, Orofacial
SciencesSan Francisco, United States
Presenting author email: sharof.tugizov@ucsf.edu
Background: The incidence of HPV-associated lesions is higher in
HIV-infected than in HIV-uninfected individuals. Oral and anogenital
mucosal epithelia of HIV/AIDS-positive individuals contain infiltrating
HIV-infected immune cells that express viral tat and gp120, and
proinflammatory cytokines TNF-a and IFN-g. These proteins may
disrupt tight junctions (TJ) of mucosal epithelium, facilitating HPV
penetration. Our aims were to investigate how HIV-associated
disruption of mucosal epithelium promotes HPV infection.
Methods: Polarized oral and cervical epithelial cells and tissue
explants from HIV-uninfected individuals were treated with recom-
binant HIV-1 tat, gp120, TNF-a and IFN-g independently and together.
The cells and tissue explants were exposed to HPV 16 pseudovirions
labeled with fluorescent dyes. Paracellular HPV penetration through
disrupted epithelium was evaluated by confocal microscopy.
Results: Treatment of oral and cervical epithelial cells with tat,
gp120, TNF-a, or IFN-g independently for 24 h did not induce
significant disruption of TJ but the combination of all 4 proteins
caused disruption of TJ in about 90% of cells. Prolonged treatment of
cells with these proteins independently for 5 days also induced
substantial disruption of TJ. Epithelial disruption mediated by these
proteins facilitated paracellular PsV passage through polarized cells-
30-45% of apically applied virions were detected in the basolateral
compartment. Treatment of oral epithelial explants with HIV tat,
gp120, TNF-a, and IFN-g led to disruption of epithelial TJ with
paracellular HPV penetration into epithelium and entry of HPV into
basal cells.
Conclusion: Our data indicate that HIV tat, gp120, TNF-a, and/or
IFN-g in the epithelial microenvironment disrupt epithelial TJ in a
time-dependent manner. Alone or together, they potentiate HPV
penetration into basal epithelial cells where HPV infection is
initiated. Interference with the effects of these proteins may be
useful to reduce the risk of HPV infection when applied topically to
at-risk genital mucosal epithelium prior to sexual exposure.
THPDA0105
Prevalence and genotypic variability of TT virus are
extremely high in HIV-1-infected adults in the Lampang HIV-
1 cohort in northern Thailand
H. Thaisri1, M. Moriuchi2, N. Tsuchiya3, A. Rojanawiwat1,
P. Pathipvanich4, P. Sawanpanyalert1, K. Ariyoshi3 and H. Moriuchi2
1National Institute of Health, Bangkok, Thailand. 2Nagasaki University
Graduate School of Biomedical SciencesDepartment of Molecular
Microbiology and Immunology, Nagasaki, Japan. 3Nagasaki
University, Institute for Tropical Medicine, Nagasaki, Japan. 4Lampang
Hospital, Lampang, Thailand
Presenting author email: hiromori@nagasaki-u.ac.jp
Background: TT virus is genetically variable and widespread among
the general population without apparent pathological effects. It has
been detected in the peripheral blood and a variety of body fluids
such as semen and cervical fluids. Studies from North America and
Europe have reported that TTV infection is more prevalent in HIV-1-
infected individuals than in healthy control, but its prognostic
significance has been controversial. No study has been reported
for TTV co-infection in HIV-1-infected Asian people. This study was
aimed to demonstrate prevalence, genotypic variability and prog-
nostic significance of TTV coinfection in northern Thailand HIV
cohort.
Methods: A total of 756 HIV-1-infected adults were enrolled in the
Lampang HIV cohort in northern Thailand, and their blood samples
were collected. HIV-1 plasma viral loads and CD4 counts were
measured at enrollment, and their clinical courses had been
monitored. 40 healthy Japanese adults were also tested as controls.
DNA of 5 TTV genogroups (G1 to G5) was detected by PCR using
genogroup-specific primer pairs.
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Results: 753 (99.9%) of 754 HIV-1-infected adults were infected with
any genogroup of TTV: G1 (700/754, 93%), G2 (0/754, 0%), G3a (740/
754, 98%), G3b (732/754, 97%), G4 (601/754, 80%) and G5 (562/754,
75%). On the other hand, 38 (95%) of 40 healthy Japanese adults
were infected with any TTV genogroup: G1 (63%), G2 (3%), G3a
(70%), G3b (68%), G4 (63%) and G5 (20%). Infection with more than
one genogroup is more common in HIV-1-infected adults (99%) than
in controls (68%). 62% HIV-1-infected and only 13% healthy adults
were infected with all of G1, G3a, G3b, G4 and G5.
Conclusion: TTV infection is highly prevalent in both HIV-1-infected
and uninfected Asian adults; however, mixed genogroups were much
more common in the former. Correlations between certain TTV
genogroup or TTV loads and CD4 counts or HIV-1 load will be
determined.
A56 - Novel assays of immune responses
TUAA0105
A universal nanoparticle cell secretion capture assay for the
study of HIV-1-positive tissues
W. Fitzgerald and J.-C. Grivel
NIH, NICHD, Bethesda, United States
Presenting author email: grivelj@mail.nih.gov
Background: Secreted proteins play an important role in intercellular
interactions, especially between cells of the immune system.
Infection of human lymphoid tissues by HIV-1 may alter secretion
patterns. Here, we describe a novel, easy, inexpensive, and versatile
method, which allows the identification and isolation of a living cell
actually secreting any protein of interest.
Methods: We coupled carboxylated magnetic iron oxyde nanopar-
ticles (IONPs) or quantum dots to polyclonal goat anti-mouse
IgG(HL) antibodies (GAM) and used them as a platform to bind
a cell-specific antibody, conferring cell targeting, and an antibody
specific for a secreted protein. Purified complexed IONPs form an
affinity matrix on the cell surface and capture the cell-secreted
product, which can then be detected on the surface of the secreting
cell by another secreted-protein-specific labeled antibody.
Results: GAM-IONPs complexed with anti-CD45 antibody and either
anti-IL-2 or anti-IFNgamma. This capture assay was as efficient as a
commercial assay and intracellular cytokine staining in identifying
cells that secrete IL-2 and IFNg. Respectively, these assays detected
IL-2 secretion on 16.994%, 14.791.8% and 16.391.4% of T cells
(N6, PB0.88) in activated PBMC cultures. Similarly, IFNg secretion
was detected equally by these three assays. Quantum dots can be
used in place of IONPs and allowed similar detection of cytokines as
well as fluorescent targeting of cells. The capture assay also detected
the secretion of MIP-1a, MIP-1b and RANTES for which no
commercial assays are available, and levels were comparable to
intracellular staining. This method is amenable to multiplexing and
several cytokines may be detected on the same cells.
Conclusion: We have developed a versatile secretion capture assay,
which allows the detection of any secreted protein of interest, and
does not compromise cell viability. This method is useful in under-
standing modifications to cytokine secretion induced by viruses such
as HIV-1.
A57 - Novel assays for virological
monitoring
TUPDE0203
Evaluation of the use of dried blood spots for viral load
monitoring in resource-limited settings in Zimbabwe
S. Ngwende1, B. Mudenge2, D. Madzimure2 and G. Mudenge2
1National Microbiology Reference Laboratory, Ministry of Health and
Child Welfare, Harare, Zimbabwe. 2Flow Cytometry Laboratory,
Harare, Zimbabwe
Presenting author email: stngwende@gmail.com
Background: Monitoring of antiretroviral treatment (ART) with
human immunodeficiency virus (HIV) viral loads, is rarely available
in resource-limited settings because of the high costs, stringent
requirements for storage and transport of plasma. Monitoring of
antiretroviral therapy (ART) with HIV-1 viral load assays to determine
virological treatment failure and to decide when to change to second
line therapy is highly recommended. Requirements for -80 degrees
Celsius freezers for sample storage prohibit implementation of this
level of care in resource poor settings. Dried blood spots (DBS) can
be used as an alternative to plasma, but the use of DBS for HIV-1
assays has not been assessed in Zimbabwe. This study investigates
the performance of DBS for HIV viral load monitoring of patients on
ART in Zimbabwe.
Methods: Parallel forty eight (48) plasma samples and 48 DBS
samples were used in this study. They were selected from samples
stored at Flow Cytometry Laboratory, Zimbabwe, collected from
patients with ART failure and who were being monitored for HIV
drug resistance. Viral load assays were performed on 48 samples
using plasma and dried blood spots methods. Plasma was separated
and frozen at -80 degrees Celsius and DBS were kept at room
temperature for 30days.
Results: The correlation between plasma and DBS viral load was high
(R20.75). Mean difference was 0.05 log10 copies/mL (SD 0.58),
and only 8 samples showed 1 log10 difference. Sensitivity and
specificity of DBS to detect virological failure (plasma viral load
400 copies/mL) was 82.5 and 93.1%, respectively.
Conclusion: There was a very good correlation between DBS stored
at room temperature for 30 days and plasma viral load assays. The
evaluation shows that DBS can be a feasible and reliable method for
virological monitoring of patients on ARVs in rural areas with
transport facilities for referring samples to a central laboratory.
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